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Abbreviations
Chemical substances and Drugs
AG490: ct-Cyano-(3,4-dihydroxy)-N-benzylcinnamide
AMPA: ct-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid
CHE: 1,2-Dimethoxy-12-methyl[1,3]benzodioxolo[5,6-c] phenanthridinuim cloride
(chelerythrine chloride)
DNQX: 6,7-Dinitroquinoxaline-2,3-dione
Ifenprodil: 2-(4-Benzylpiperidino)-1-(4-hydroxyphenyl)-1-propanol hemitartrate
KN-93:2-[N-(2-Hydroxythyl)-N-(4-methoxy-benzenesulfonyl)]amino-N-(4-
chlorocinnamyl)-N-methylbensylamine
METH: Methamphetamine hydrochloride
MPEP: 2-Methyl-6-(phenylethynyl)-pyridine hydrochloride
MRP: Morphine hydrochloride
NMDA: N-Methyl-D-aspartate acid
NPC-15437:S-2,6-Diamino-N-[(1-[1-oxotridecyl]-2-piperidinyl)methyl]hexamide
dihydorochloride
PDBu: Phorbol 12, 13-dibutyrate
PPF: 3-methyl-1-(5-oxohexyl)-7-propylxanthine (propentofylline)
U73122:1-(6-[([17P]-3-methoxyestra-1,3,5[10]-trien-17-yl)-IH-pyrrole-2,-dione
Buffers
BSS: Balanced salt saline
PBS: Phosphate-buffered saline
Brain regions
CG: Cingulate cortex
CPu: Corpus striatum
N.Acc.: Nucleus accumbens
VTA: Ventral tegmental area
Endogenous substances
EGF: Erythropoietic growth factors
i
GFAP: Glial fibri11ary acidic protein
G-CSF: Granulocyte-colony stimulating factor
GM-CSF: Granulocyte-macrophage colony-stimulating factor
IFN: Interferon
IP-10: Interferon-y-inducible protein-10
IL: Interleukin
M-CSF: Macrophage-colony stimulating factor
MCP: Monocyte chemoattractant protein
NeuN: Neuronal nuclei
RANTES: Regulated upon activation normal T cell expressed and secreted
sTNFR-1: Soluble tumor necrosis factor receptor-1
TGF: Transforming growth factor
Receptors
mGIuR: Metabotropic glutamate receptor
Enzymes and intracellular messengers
CaMKII: Calciumlcalmodulin-dependent protein kinase II
Jak/STAT: Janus kinase/signal transducer and activator of transcription
PKC: Protein kinase C
PLC: Phospholipase C
Serum
FBS: Fetal bovin serum
HS: Horse serum
Injection routes
i.c.v.: Intracerebroventricular
i.p.: Intraperitoneal
s.c.: Subcutaneous
Others
ACM: Astrocyte-conditioned medium
ii
ANOVA: Analysis of variance
CNS: Central nervous system
DMEM: Dulbecco's modified Eagle's medium
IgG: Immunoglobulin G
[Ca2' ]i: Intracellular Ca2' concentration
LTP: Long-term potentiation
MCM: Microglia-conditioned medium
METH-ACM: Astrocyte-conditioned medium collected from methamphetamine-treated
astrocytes
MRP-ACM: Astrocyte-conditioned medium collected from morphine-treated astrocytes
NSC: Neural stem cell
p-PKC: Phosphorylated-protein kinase C
iii
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General Introduction
Astrocytes
  There are two categories of cells in the central nervous system (CNS); neurons and
adjacent glial cells including astrocytes, microglia and oligodendrocytes. Throughout
the last century, most neurophysiologists believed that synaptic transmission in the brain
was mediated by neurons. Ironically, glial cells were considered to be minor players in
the mammalian CNS, even though they outnumber neurons 10-fold. Glial cells were
simply thought to function as passive support cells, bringing nutrients to and removing
waste from neurons.
  Over the past decade, however, an increasing number of observations have
progressively challenged this classical view. Glial cells have important physiological
propenies as they relate to CNS homeostasis'). Moreover, glial cells affect neuronal
function through the release of neurotransmitters, neurotrophic factors, cytokines,
chemokines and extracellular matrix, guide neuronal development, contribute to the
metabolism of neurotransmitters, and regulate extracellular pH and ion levels2'5).
  Astrocytes are a subpopulation of glial cells in the CNS. Astrocytes have
traditionally been considered to be structural elements within the CNS with the main
function of maintaining nerve tissue. Astrocytes come in close contact with several
cellular components of the brain parenchyma including blood vessels, pial surfaces,
neurons and other glial cells. Astrocytes have a large variety of receptors for
neurotransmitters and hormones, including glutamate receptors68), ATP receptors9' iO) and
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dopamine receptors"' '2), which are coupled to various intracellular signaling cascades`'
'3' i`). Astrocytes are known to exhibit a form of excitability and communication based
on changes in the intracellular Ca2' concentration ([Ca2']i), which can be stimulated by
neuronal synaptic activity, and release glutamate, ATP and nitric oxide that signal back
to adjacent neurons and other astrocytesi4i8). More recently, astrocytes have been
reported to promote axonal extension and neuronal migration, whereas astrocyte-
derived cues also play a critical role in the pathological process by forming boundaries
and retarding axonal outgrowthi9-n).
  Astrocytes are immunocompetent cells in the CNS23-as). Both in vitro and in vivo
studies have documented the ability of astrocytes to produce interleukin (IL)-1, -6 and -
10; interferon (IFN)-ct, and -P; granulocyte-macrophage colony-stimulating factor (GM-
CSF), macrophage-colony stimulating factor (M-CSF), and granulocyte-colony
stimulating factor (G-CSF); and tumor necrosis factor-ct (TNF-ct) and transforming
growth factor-P (TGF-P). Astrocytes also produce chemokines including regulated on
activation normal T-cell expressed and secreted (RANTES), IL-8, monocyte
chemoattractant protein-1 (MCP-1) and IFN-y-inducible protein-10 (IP-10).
Activation of astrocytes
  Astrocytes undergo a process of proliferation, morphological changes, and
enhancement of glial fibrillary acidic protein (GFAP) expression, which has been
referred to as the activation of astrocytes or astrogliosis2628). Astrocytes become
activated in response to many CNS pathologies29'30), such as stroke, trauma, growth of a
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tumor or neurodegenerative disease, such as Alzheimer' disease and Parkinson's
disease.
  AIthough the activation of astrocytes has been considered to be the major impediment
to axonal regrowth after an injury, the formation of a glial barrier around a lesion site is
also an advantage, because it isolates the still-intact CNS tissue from secondary
lesions2"28). In fact, the role of GFAP in neurite outgrowth has been assessed in vitro28'
3"33). Collectively, the activation of astrocytes and astrogliosis are very complex
phenomena, involving interactions of several cell types with neurons, leading eventually
to neuron survival or death and axonal regeneration.
Role of astrocytes in central synaptic plasticity
  It has been estimated that individual astrocytes in the adult rodent brain may
ensheathe and interact with as many as 10,OOO synapses. Accumulating evidence
suggests that astrocytes may actively panicipate in synaptic plasticity3`3'). In vitro
studies have found that astrocytes exert powerful control over the number of CNS
synapses3`38). Astrocytes are also essential for postsynaptic function, and are required
for synaptic stability and maintenance3438). In fact, astrocytes and other perisynaptic
glia, such as Schwann cells, release soluble proteinaceous signals that profoundly
enhance synaptic activity by nearly 100-fold3`'3D. Moreover, astrocytes induce an
increase in the number of synapses in these cells35' 3n. In addition, these new synapses
are ultrastructurally normal and functiona135' 3D. Taken together, these findings indicate
that astrocytes profoundly increase the number of synapses that form between CNS
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neurons in vitro. These reports also provide evidence that the number of synapses is
not solely determined by the intrinsic properties of neurons but can be powerfully
controlled by extracellular signals from adjacent astrocytes. Recent studies
increasingly implicate astrocytes in vivo as participants in activity-dependent structural
and functional synaptic changes throughout the mammalian CNS3'• 38).
Dopaminergic and glutamatergic neurotransmission in the development of
synaptic plasticity induced by drugs of abuse
  Studies of human addicts and behavioral studies in rodent models of addiction
indicate that key behavioral abnormalities associated with addiction are extremely long-
lived. Drugs of abuse are chemically divergent molecules with very different initial
activities. However, many pharmacological and biochemical findings support the idea
that long-term exposure to psychostimulants induces neuronal plasticity39'`i).
  Among brain neurotransmitters, dopamine has been more extensively implicated in
the mechanism of drug addiction, not only as a substrate of psychostimulant reward but,
more generally, also as a substrate of drug-related learning and neuroadaptation. A
prominent amount of psychostimulant-related actions is thought to depend on the
activation of the mesolimbic dopamine system`2-"); this activation involves increased
firing of dopamine neurons in the ventral tegmental area (VTA) of the midbrain and a
subsequent increase of dopamine released into the nucleus accumbens (N.Acc.).
  On the other hand, several lines of evidence suggest that glutamatergic projection to
the N.Acc. originating from the prefrontal cortex and amygdala`S regulates emotional
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and behavioral processing. Glutamate is a major fast excitatory neurotransmitter in the
CNS, and glutamate receptors have been shown to play important roles in synaptic
plasticity such as long-term potentiation (LTP), which is thought to underlie
physiopathological phenomena, neuronal development, synaptic plasticity and
synaptogenesis`6-`8). Therefore, it is likely that the long-lasting synaptic adaptations in
dopaminergic andlor glutamatergic neurotransmission provide a neuronal framework for
altered behavioral processing underlying the development of psychological dependence
on drugs of abuse.
Protein kinase C
  Protein kinase C (PKC) plays a major role in cellular regulatory and signaling
processes involving the phosphorylation of proteins, modulation of neuronal function,
synthesis and release of neurotransmitters and regulation of receptors49' so).
  PKC is activated by diacylglycerol, which can be generated by phospholipase C
(PLC). There are three mammalian PLC form families: PLCP, PLCy and PLC65').
All known forms of PLCP isoforms are stimulated to various extents by ct subunits of
the G,m family. PLCB2 and P3 are also activated by Py subunits of the G-protein. In
contrast, PLCy isoforms are stimulated mainly through receptor tyrosine kinases.
  Several lines of evidence have demonstrated that activated PKC plays a key role in
the modulation of synaptic plasticityi9' 2" S2). Considerable evidence suggests that the
activation of PKC in the brain modulates the development of sensitization to drugs of
abuse, such as methamphetamine (METH)53), cocaine") and morphine (MRP)5$.
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Moreover, PKC also plays a positive regulatory role in the development and/or
expression of rewarding effects induced by METH53), amphetamine56) and MRP5D.
These findings strongly suggest that activated PKC in the brain may play a substantial
role during the development of dependence and sensitization induced by chronic
treatment with drugs of abuse.
Astrocytic responses to drugs of abuse
  Many studies have documented that astrocytes show hypertrophy and proliferation
upon treatment with drugs of abuse at neurotoxic doses. For example, Pu and
Vorheesss) have shown that repeated in vivo treatment with METH (4 injections of 10
mglkg, i.p. at 2 hr intervals) induced depletion of tyrosine hydroxylase-positive neurons
and proliferation of astrocytes in rat striatum. More recently, Guilarte et al.59) reported
that repeated administration of METH (4 injections of 15 mg/kg, i.p. at 2 hr intervals)
induced the loss of dopamine transporters, serotonin transporters and vesicular
monoamine transporter type-2 with the activation of astrocytes and microglia in rat
striatum. Fattore et al.oo) also demonstrated that repeated daily administration of
cocaine (20 mg/kg, i.p.) caused the enhancement of GFAP expression in the mouse
dentrate gyrus. These observations raise the possibility that astrocytes may play an
important role in psychostimulant-induced neurodegeneration. However, relatively
little is known about the mechanism that underlies psychostimulant-induced astrocytic
responses during the development of dependence, even if astrocytes are considered to
play a critical role in long-term synaptic plasticity in the CNS.
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                            Aim and Scope
  The aim of the present study was to investigate the role of astrocytes in the
development of central synaptic plasticity induced by chronic treatment with drugs of
abuse. Behavioral, neurochemical and biochemical experiments were conducted.
The specific aims of the proposed research were:
In Chapter 1:
  To ascertain the influence of in vitro treatment with drugs of abuse on astrocytes, I
investigated whether in vitro treatment with METH and MRP could affect the
morphology of astrocytes in mouse purified cortical astrocytes and neuronlglia co-
cultures. Furthermore, I also explored the difference between METH and MPR in the
PKC-dependent expression and maintenance of the activation of astrocytes. In
addition, I examined the in vivo astrocytic response during the development of
sensitization to hyperlocomotion induced by chronic treatment with METH.
In Chapter 2:
  To clarify the role of glutamatergic neurotransmission and its association with PKC in
neuron-astrocyte communication, in vitro studies were undertaken to investigate the
mechanism underlying glutamate-induced Ca2' response in both neurons and astrocytes.
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Moreover, I have demonstrated functional and morphological changes in glutamatergic
neurotransmission induced by METH.
In Chapter 3:
  To clarify the substantial role of astrocytes in the development of rewarding eflfects
induced by drugs of abuse, behavioral studies were undertaken to investigate whether
astrocyte-related soluble factors affect the expression of rewarding effects induced by
METH and MRP. I also explored the implication of Janus kinase/signal transducer and
activator of transcription (Jak/STAT) pathway--dependent astrogliosis and
astrogliogenesis during the development of rewarding effects induced by METH and
MRP.
8
Ethics
  The present study was conducted in accordance with the Guiding Principles for the
Care and Use of Laboratory Animals, as adopted by the Committee on Animal Research
of Hoshi University, which is accredited by the Ministry of Education, Culture, Sports,
Science and Technology of Japan. Every effort was made to minimize the numbers
and any suffering of animals used in the following experiments. Animals were used
only once in the present study.
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Enhancement of protein
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Introduction
  METH and cocaine are strongly addictive psychostimulants that dramatically affect
the CNS, and are highly abused drugs worldwide. Abuse of psychostimulants leads to
the development of psychotic symptoms that resemble those of paranoid
schizophrenia6i). In rodents, it has been shown consistently that repeated exposure to
psychostimulants results in a progressiye and enduring enhancement in the motor
stimulant effect elicited by a subsequent drug challenge, which termed behavioral
sensitization53'55'62). Accumulating evidence suggests that the behavioral sensitization
induced by psychostimulants may be accompanied by long-lasting neural plasticity63-65),
which may involve structural modifications in the dopaminergic and/or glutamatergic
systems.
  The present study was undertaken to investigate the mechanism of METH- and MRP-
induced astrocytic activation in purified cortical astrocytes and conical neuron/glia co-
cultures. I also explored the difference betweeR METH and MRP in the maintenance
of astrocytic activation in cultured cells and behavioral sensitization in mice.
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Materials and Methods
Tissue Processing
  Purified cortical astrocytes were grown as follows; cerebral cortices were obtained
from newborn ICR mice (Tokyo Laboratory Animals Science Co., Ltd., Tokyo, Japan),
minced, and treated with trypsin (O.025 9o, Invitrogen Co., Carsbad, CA, USA)
dissolved in phosphate-buffered saline (PBS) solution containing O.02 9o L-cysteine
monohydrate (Sigma-Aldrich Co., St. Louis, MO, USA), O.5 qo glucose (Wako Pure
Chemicals Ind., Ltd., Osaka, Japan) and O.02 9o bovine serum albumin (Wako Pure
Chemicals Ind., Ltd.). After enzyme treatment at 37 eC for 15 min, cells were
dispersed by gentle agitation through a pipette and plated on a flask. One week after
seeding in Dulbecco's modified Eagle's medium (DMEM, Invitrogen Co.) supplemented
with 5 9o fetal bovine serum (FBS, Invitrogen Co.), 5 9o heat-inactivated (56 OC, 30
min) horse serum (HS, Invitrogen Co.), 10 U/mL penicillin and 10 pg/ml streptomycin
in a humidified atmosphere of 95 9o air and 5 9o C02 at 37 OC, the flask was shaken for
12 hr at 37 eC to remove non-astrocytic cells. The cells were seeded at a density of 1 x
105 cellslcm3. The cells were maintained for 3 to 10 days in DMEM supplemented
with 5 9o FBS, 5 9o HS, 10 UlmL penicillin and 10 ptg/mL streptomycin in a humidified
atmosphere of 95 9o air and 5 9o C02 at 37 OC.
  Cortical neuron/glia co-cultures were grown as follows; cerebral cortex was obtained
from newborn ICR mice (Tokyo Laboratory Animals Science Co.), minced, and treated
with papain (9 UlmL, Worthington Biochemical, Lakewood, NJ, USA) dissolved in
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PBS solution containing O.02 9o L-cysteine monohydrate, O.5 9e glucose and O.02 9o
bovine serum albumin. After enzyme treatment at 37 eC for 15 min, cells were
seeded at a density of 2 x 106 ceils/cm3. The cells were maintained for 7 days in
DMEM supplemented with 10 9o FBS, 10 U/mL penicillin and 10 ptg/mL streptomycin.
On day 8, the cells were treated with drugs.
Drug treatment and immunohistochemistry
  At day 3-7 in vitro, the cells were treated with either normal medium,
methamphetamine hydrochloride (METH, O.Ol-1000 pM, Dainippon Pharmaceutical
Co. Ltd., Osaka, Japan), a selective protein kinas C (PKC) inhibitor chelerythrine
chloride (CHE, 10 nM, Sigma-Aldrich Co.) + METH (1-100 ptM), morphine
hydrochloride (MRP, O.1-1000 pM, Sankyo Co., Ltd., Tokyo, Japan), MRP (10-100
ptM) + CHE (10 nM) or CHE (10-100 nM). The treatments lasted for 1-3 days. The
cells were then identified by immunofiuorescence using a rabbit polyclonal antibody to
GFAP (1:1000; Chemicon International, Inc., Temecula, CA, USA), a mouse polyclonal
antibody to GFAP (1:1000, Chemicon, International, Inc.), a rabbit polyclonal antibody
to phosphorylated-protein kinas C (p-PKC, 1:400; Cell Signaling Technology Inc.,
Beverly, MA, USA), or a rabbit polyclonal antibody to cleaved caspase-3 (1:100, Cell
Signaling Technology Inc., Beverly, MA, USA), followed by incubation with Alexa
488-conjugated goat anti-rabbit IgG (1:4000) or Alexa 546-conjugated goat anti-rabbit
IgG (1:4000) for GFAP, Alexa 488-conjugated goat anti-rabbit IgG (1:4000) for p-PKC,
and Alexa 488-conjugated goat anti-rabbit IgG (1:100oo) for cleaved caspase-3.
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Images were collected using a Radiance 2000 laser-scanning microscope (BioRad,
Richmond, CA, USA). The experjments were repeatedly performed by, at Jeast, 3
independent culture preparations.
  The intensity of GFAP-like immunoreactivity was measured with a computer-assisted
system (NIH Image). The upper and lower threshold intensity ranges were adjusted to
encompass and match the immunoreactivity to provide an image with immunoreactive
material appearing ifi black pixels, and non-immunoreactive material as white pixels.
The area and intensity of pixels within the threshold value representing
immunoreactivity were calculated. I randomly chose 10 areas (80 x 80 pixels) for
calculation of GFAP-like immunoreactivity in each image (512 x 512 pixels). The
intensity of GFAP-like immunoreactivity was expressed as a percent increase (mean Å}
SEM) with respect to that in control cells.
Evaluation of astrocytic stellation
  In order to evaluate the astrocytic stellation, purified cortical astrocytes were cultured
on 24 well plates and treated with METH (O.Ol-100 ptM) or METH (1-100 pM) + CHE
(10 nM) for 1-3 days. The cells were fixed in 4 9o paraformaldehyde and stained with
cresyl yiolet (O.1 9o, ICN Biomedica}s, Aurora, OH, USA) to determine the percentage
of stellate cells in cultures. Cells with processes longer than their perinuclear
diameters were defined as stellate cells. Stained cells were mounted on glass slides
and viewed under transmitted light using a microscope with a 10 x objective lens (IX 70,
Olympus Optical, Tokyo, Japan). For each coverslips, four randomly chosen fields
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were counted (about 170 cells in each field), and the percentage of stellate cells was
determined. Each experimental condition was repeated from 4 independent culture
preparations. The percentage of stellate cells was expressed as mean Å} SEM.
Confocal Ca2' imaging
  Cells were loaded with 10 pM fluo-3 acetoxymethyl ester (Dojindo molecular
Technologies, Inc., Kumamoto, Japan) for 90 min at room temperature. After a further
20-30 min of de-esterification with the acetoxymethyl ester, the coverslips were
mounted on a microscope equipped with a confocal Ca2' imaging system (Radiance
2000, BioRad). Fluo-3 was excited with the 488 nm line of an argon-ion laser and the
emitted fluorescence was collected at wavelengths År 515 nm, and average baseline
fluorescence (Fo) of each cells was calculated. To compensate for the uneven
distribution of fluo-3, self--ratios were calculated (Ratio = FIFo).
  Dopamine hydrochloride (1-100 ptM, Sigma-Aldrich Co.) or glutamate (1-100 ptM,
Wako Pure Chemicals Ind., Ltd.) was perfused for 30 sec at 5 mLlmin at room
temperature in cells followed by superfusion of balanced sait saline (BSS, pH 7.4)
containing 150 mM NaCl, 5.0 mM KCI, 1.8 mM CaCl,, 1.2 mM MgC12, 25 mM N-2-
hydroxyethylpiperazine-N'-2-ethaneslufonic acid and 10 mM D-glucose.
Locomotor assay for METH and MRP
  Male ICR mice (20-25 g) were housed at a room temperature of 23 Å} 1 eC with a 12-
hr light-dark cycle (lights on 8:OO to 20:OO). Food and water were available ad
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libitum.
  The locomotor activity of mice was measured by an ambulometer (ANB-M20,
O'Hara, Tokyo, Japan) as described previously66). Briefly, a mouse was placed in a
tilting-type round activity cage of 20 cm in diameter and 19 cm in height. Any slight
tilt of the activity cage caused by horizontal movement of the animal was detected by
microswitches. Total activity counts in each 10-min segment were automatically
recorded for 30 min prior to the injections and for 180 min following METH
administration.
  According to previous reports55' 6D, a repeated injection paradigm was used in which
animals were treated with an injection of METH (2 mg/kg, s.c.) or MPR (10 mglkg,
s.c.) every 96 hr to induce sensitization to METH- or MRP-induced hyperlocomotion.
Total activity was counted for 3 hr after each treatment.
  To investigate the implication of PKC in the development of sensitization to METH-
induced hyperlocomotion, mice were pretreated with saline or a selective PKC inhibitor
S-2,6-diamino-N-[(1-[1-oxotridecyl]-2-piperidinyl)methyllhexamide dihydorochloride
(NPC-15437: 1 mglkg, s.c., Sigma-Aldrich Co.) 30 min prior to METH (2 mglkg, s.c.)
treatment.
Immunohistochemistry using brain-slice sections
  Twenty four hr after the last METH treatment, animals were deeply anesthetized with
sodium pentobarbital (50 mglkg, i.p.) and perfused transcardially with 4 9o
paraformaldehyde in O.1 M PBS. Then, the brains were removed quickly after
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perfusion and thick coronal section of the forebrain including the N.Acc. and cingulate
cortex (CG) region was initially dissected using brain blocker. The coronal section of
the midbrain was post-fixed in 4 9o paraformaldehyde for 2 hr. After the brains were
permeated with 20 9o sucrose for 2 days and 30 9o sucrose for 2 days, they were frozen
in an embedding compound (Sakura Finetechnical, Tokyo, Japan) on isopentane using
liquid nitrogen and stored at -30 eC until used. Frozen coronal sections (8 pm) were
cut in a cryostat, and thaw-mounted on poly-L-lysine-coated glass slides.
  Each primary antibody was diluted in O.Ol M PBS containing 10 9o normal horse
serum [1:10 GFAP (Nichirei Co., Tokyo, Japan)] and was incubated twice overnight at 4
OC. The antibodies were then rinsed and incubated with each secondary antibody for 2
hr at room temperature. For each labeling, Alexa 488-conjugated goat anti-rabbit IgG
for GFAPwas diluted 1:1200 in PBS containing 10 9o normal horse serum.
Statistical analysis
  The data of GFAP-like immunoreactivity, astrocytic stellation and confocal Ca2'
imaging are presented as the mean Å} SEM. The statistical significance of differences
between the groups were assessed by one-way analysis of variance (ANOVA) with
Student's t-test. The statistical significance of differences between the groups were
assessed by two-way ANOVA followed by the BonferronilDunn multiple-comparison
test.
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                                Results
METH-induced astrocytic activation
  Treatment with METH (10 ptM) for 3 days caused a robust activation of purified
cortical astrocytes, as detected by a stellate morphology and an increase in the level of
GFAP-like immunoreactivity compared to that in normal medium-treated cells (Figure
1-IA). As shown in Figure 1-IB, treatment with METH (1-100 pM) for 1-3 days
significantly increased the number of stellate astrocytes in purified cortical astrocytes.
Although 1 day treatment with METH eyen caused a significant stellation in purified
cortical astrocytes, 3 days treatment with METH (10-100 ptM) showed a drastic
stellation. In addition, this activation of astrocytes was partially reversed by treatment
with the specific PKC inhibitor CHE (Figure 1-IA, B), indicating the possible
implication of PKC in this event. Immunohistochmical staining with an antibody to p--
PKC confirmed that treatment with METH increased the immunoreactiviy of p-PKC in
astrocytes (Figure 1-IC). These results suggest that astrocytic PKC is involved in
MEHT-induced astrocytic activation. Treatment with METH (10-100 ptM) for 3 days
also caused a robust atrocytic activation in cortical neuron/glia co-cultures, and this
activation was reversed by co-treatment with CHE (Figure 1-2A, B).
  I next investigated whether treatment with METH could induce any functional
changes in astrocytes. Either dopamine (1-100 ptM) or glutamate (1-100 ptM)
produced a transient increase in [Ca2'li in purified cortical astrocytes (Figure 1-3A, B,
C). The Ca2' responses to dopamine and glutamate in astrocytes were significantly
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enhanced by 3 days of treatment with METH (10 pM, 3 days, Figure 1-3A, B, C).
Morphine-induced astrocytic activation
  To compare its effects with those of METH, I investigated the effect of MRP in
astrocytes. Unlike METH, treatment with MRP (1-1000 ptM) for 1-3 days did not
produce morphoiogical changes in the activation of purified cortical astrocytes (Figure
1-4A, B). In contrast to MRP treatment in purified cortical astrocytes, treatment with
MRP (10-100 ptM) for 3 days activated GFAP-positive astrocytes in cortical neuron/glia
co-cultures (Figure 1--4C, D), and this activation was partially attenuated by CHE (10
nM).
Different maintenance of METH- and MRP-induced astrocytic activation
  I next explored the difference between METH and MRP in the maintenance of
astrocytic activation. Treatment with METH (10 pM) for 1 day caused the activation
of GFAP-positive astrocytes in cortical neuronlglia co-cultures (Figure 1-5A). The
METH-contained medium was then switched to normal medium, and the cells were
cultured for additional 2 days. It is of interest to note that the METH-induced increase
jn the JeveJ of GFAP-immunoreactivity stjll remained after an additionai 2 days of
cultured with normal medium (Figure 1-5A). Treatment with MRP (10 yM) for 1 day
also caused the activation of GFAP-positive astrocytes in cortical neuron/glia co-
cultures (Figure 1-5B). The MRP-containing medium was then switched to normai
medium, and the cells were cu!tured for additional 2 days. Unlike METH, the MRP-
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induced increase in the level of GFAP-immunoreactivity was reversed after an
additional 2 days of cultured with normal medium (Figure 1-5B).
Long-lasting maintenance of behavioral sensitization to METH, but not MRP
  The repeated administration of psychostimulant drugs results in a progressive and
enduring elevation in the motor response elicited, which may be accompanied by a
long-lasting neural plasticity. Therefore, I hypothesized that the psychostimulant-
induced astrocytic activation may be reiated to behavioral sensitization. Based on the
data presented above and the hypothesis, I next investigated whether repeated in vivo
treatment with METH could cause a long-lasting maintenance of behavioral
sensitization to METH-induced hyperiocomotion.
  To clarify the development of sensitization to METH- or MRP-induced
hyperlocomotion, mice were given five times with METH (2 mglkg, s.c.) or MRP (10
mg/kg, s.c.) every 96 hr. Repeated injection of either METH or MRP produced a
progressive elevation of the METH- or MRP-induced locomotor-enhancing effect,
indicating the development of sensitization to METH- or MRP-induced
hyperlocomotion (P Åq O.Ol, first session versus fifth session, Figure 1-6A, B).
Intriguingly, the METH-induced sensitization to hyperlocomotion was maintained even
after 2 months withdrawal following intermitted METH administration (Figure 1-6A).
However, the MRP-induced sensitization was reversed by 2 months withdrawal
following intermitted MRP administration (Figure 1-6B).
20
METH-induces neuronal cell death
  METH has been recognized as a drug of abuse that induces nerve terminal
degeneration and neuronal apoptosis in the mammalian brain59' os). I therefore
confirmed whether in vitro treatment with high concentration of METH or MRP could
induce neuronal cell death. Treatment with METH (100ptM, 1 mM) for 3 days in
cortical neuron/glia co-cultures caused the robust activation of cleaved caspase-3, which
is a marker of neuronal death (Figure 1-7A). However, unlike METH, high
concentration of MRP faiied to produce the caspase-3 activation (Figure 1--7B).
In vivo Astrocytic Responses by METH
  Finally, I investigated in vivo astrocytic responses during the development of METH-
induced sensitization. In order to investigate the direct involvement of PKC in the
development of sensitization to METH-induced hyperlocomotion, mice were given
intermittently METH (2 mglkg, s.c.) in combination with a specific PKC inhibitor NPC-
15437 (1 mg/kg, s.c.). Intermittent co--administration of NPC-15437 abolished the
development of sensitization to METH-induced hyperlocomotion (Figure 1-8).
  I also confirmed that repeated in vivo treatment with METH under the present
schedule failed to cause the neuronal cell death; the present schedule of treatment with
METH had no effect on the caspase-3 activity in the caudate putamen (data not shown).
Immunohistochemical studies were also performed in order to investigate the change in
GFAP-IR levels in the CG (Figure 1-9A) and N.Acc. (Figure 1-9B) following
intermittent treatment with METH. The GFAP-immunoreactivity level was clearly
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increased in METH-sensitized rnice compared to those in mice that had been repeatedly
treated with saline (Figure 1-9A, B). This increase in GFAP-IR }evel in METH-
sensitized mice was completely aboiished by intermittent co-administration of NPC-
15437 (Figure 1-9A, B).
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Figure 1-1 Trea"nent wl,th niethaniphctaniine (METH)causes astr(x/iytic acti vation in puriiHied coiliual
astroc:y'tes. (,AL) Purifiecl cotttic`al astrocÅr,tc:' were incubated with nermal mecliLim. N,IHITH (10 yM) or
ME'I'H + chelerÅr'thrinc (CIIE. 10 nM} for 3 duÅr•s. The `:ells xvcre stained xvilh a rabb:,1 polÅr,elenal
antibedN' to GFf-XP. cB) Purified uorticu] astrt.}L'x'tes xverc incubalecl xvith normal mcdium. METH (O.O]-
IOO yevb or )vlh]'I'H cl-[OO yM) + CHE cIO nPv'b t'cr 1-3 daÅrs. A- /rrocytic activation as .shown b.y a
stellate n]orpholo."År, Nvith proces,ses lon.yer than thcir perinuclcar dian]eters xi,':ts evaluatccl. I)ata
represcnt the' mean Å} SEM o'f 139-250 cells 1'rom 4 separate obscrvations. 'i:'i'pÅqO,O]. 'it*']{pÅqO.OOI:
contro] . ##ffp Åq O.OOI: x,s. eells without CHE. (C) The .L'recn ]abeled forp-PK("(pan) stainecl xvilha
rabbit l)()i.x'clonal antibody and thc red labelcd for (1]F,ALP staincd xvith a mou/e polÅr'c]ona] antibcxlÅr, arc
mestl.x overlapl)ed as År'ello"' in MF.TH-trcated astrcxL'.vtes.
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Figure 1-2 Trcatn'ient Nvith niethaniplietaniinc (METH) i'or 3 days causes astrocytic
activation in cortica] neuron!glia cc)-cttltures. (A) Cortical neui'onfglia co-culrures xi"'ere with
normai medium. TVI ETH (O.1-1(,X} stMÅr or METH ( 1-1Oe yM)+CHE OO nM) for3days. The
celis were staincd xvith a rabbit polyclonal antibodÅr, to GFAP. (B) The- intcnsit}•' ofGFAP-
like immunorcactivity of each itna.ge xvas measurcd usin.g an NIH itnage. Thc lcvel ofGFAP
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Figure 1-3 The Ca2' responses to dopamine and glutamate in astrocytes were significantly
enhanced by 3 days of treatment with maTH. (A) Traces show the dopamine (100 ptM)-evoked
increase in the intracellular Ca2' concentration in control and METH-treated astrocytes. (B)
Traces show the glutamate (100 ptM)-evoked increase in the intracellular Ca2' concentration in
control and METH-treated astrocytes, (C) The Ca2' responses to dopamine and glutamate in
controi and rvIETH-treated astrocyteg. are summarized. Data represent the mean Å} SEM of54-
72cells. "p ÅqOD5, *'pÅqO.O1 vs. control agtrocytes.
25
(A)
In purified cortical asl'recÅr'1'c/
:J/ l [e'/1
(BÅr
   s()
 t (-
 e
 •=
 - 4"
  L•
 '.4
   ,-
   d]
     Ccmtret 1 lf] 1[)- lt){M
(C) i, !] coll i•cai 1]eul'ol], LTIia bL'o-cuirul'c-s
X•t,yt" t!IVI, i d.•il-1
(D)
   4C}O
r,oo
-J
-r
=
•V
. 2{}O
'-
r
.
t-y•LJ'
1OO
()
1 lil [i,,{1 1"{}[)
i,tl'te ' ,tiU, .{ da.vsJ
Intensitv {)f GEi-SLI' immunoreacti\ity
 ="'ithout(1[]i{l()iTM}
+="ith(1[['. 1"nM)
                                                                                          ++
                                                                         {.).1 1 [() I() 1()() I(}()
   )O LUII
     ' :l•IRI'(si,,l•I,3da.vs ti'eahnenO
Figure 1-4 Motphinc (MRi:) eauses astroeÅr'riL.' activalion in cortiea] neuroni' .gliiL eo-cultures. but not in
corticiil l)urified as. trocÅr'tcs'. (ttX) Purit'iec.1 cortical as, troc.s,'tcs xvere incul)ated with tiormal medium or MRPd-
1000 FtM) i'or 3 da.x's'. "I"he cells ",ere stainccl ",ith a rabbit polÅr'clonal antibodÅr' to GFAP, {B) 1'urii'iecl
eortieiil astrocÅr'tes xverc iEk'ubuted with normal mcdium ancl MRP cI-1000 stM) i'er 1-3 days. ,Xstroe.vtic
aetivatioti :N shoxvti bÅr : stcl[ate morpholotLlÅr' "ith proces: e/ lon.ger than thc'tr perinuelear tliumetcr.s wa,s
evalualcLi. L)ala represenl thL.i menn Å} SEP,Ll ol' 175-23() uells i'rom 4' scpara{e obserx'ations. c('} ('or{ical
neuroni' glia co-cu]ture/ "cre ineubated "•ith normal mcdium. MRP(O.1-]OO tt)v'1) or MRP(R}-]00 uM)+
Cl'IE ÅqiO nrVO a'or 3 claÅr•'s. Thc eells ",ere :taincd ",ith :t rttbbit polÅr,c]ona] antibody to GFAP. {I)) 'rhe
intensily ol' GI';i5LP-like innniunoreactivity of each iinag,e xvas nieusured usinu un NIH iniage. rl'he ]evcl oi'
(IF'AP like iTninunorenctivity on I {RP- or ", v'IRI' -+- CHE-trcatecl cells is e/ pre/ sed as tt percent increase "ncan
Å} StiM) "ilh rer I)eet to tliat on cotitrol cells. ri' pÅqO.()rF). 'i"i';!'pÅqO.OO1;xs,ceTi{rol eelLs. 1/Xt/IpÅqO.OOI: x':.
,N IR P-trea teJ cell.s' .
('"nu'el -
26
In corticai ntr":.f/•}i //Jliu co-culrures
ÅqA)
(B)
)r O yull
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neu:'oni' Ltilia co-eultui'es. {iX} (.'ortical neuron,i' .ylia co-cultures xvere incubateci "'ith noi'tnal
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Figure 1-6 The difference between METH and MRP in the maintenance of behavioral
sensitization in mice. (A) Mice were treated with METH (2 mgfkg, s.c.) every 96 hr 'for five
sessions. Mice were then administered with METH (2 mgfkg, s.c.) after 2 months
withdrawal. Total activity was counted for 3 hr after each treatment ( l , 5, 9, 1 3, 17 days aiid
after 2 months withdrawal). #p Åq O,05, ##p Åq O.Ol, vs. the 1it administration. (B) Another
group of mice were given fiye interrnittent treatments morphine (1O mgfkg, s.c.) every 96 hr.
Mice were then administered with morphine (10 mgfkg, s.c.) after 2 months withdrawal,
Total activity was counted for 3 hr after the treatment (1, 5, 9, 13, 17 days and after 2
months withdrawal). "p ÅqO,05, Å}• * ÅqO,C)1, ""'pÅqO.OO1 vs. the 1Si administration.
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Figure 1-7 High c.oncentration of ME'1"H, but noL MRP, causes a neuronal cell death in cortical
neuron!ts,lia c{i)cultures. (A) Cortical neuron!glia co-cultures were incubated with normal medium
or MFJrH C1. 10, 1OO ILM. 1 mM) fbr3 days. (B) Corticiil neuroiVglia co-cultures svere incubated
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Figure 1-8 Blockade of the development of sensitization to METH (2 mg/kg, s.c.)-induced
hyperlocomotion by co-treatment with a PKC inhibitor NPC-15437 (1 mg/kg, s.c.) in mice. M]ETH (2
mglkg, s.c.) or saline was repeatedly given to mice every 96 hr, and the totaI activity was counted for 3
hr after each treatment. Repeated injection of METH produced aprogressiveeleyation ofthe rVlliTH-
induced locomotor-enhancing effect, indicating the development of sensitization to METH-induced
hyperlocomotion (Fi, ig(f=430.20, p Åq O.oo1 vs. Saline-Saline). Another groups of mice were given
intermittently with IVfiIITH in combination with NPC (1 mgfkg, s.c.) every 96 hr. NPC or salinewas
pretreated at 30 min before M[ETH administration (2 mg!kg, s.c.). Intermittent co-administration of
NPC-15437 significantly suppressed the development of sensitization to METH-induced
hyperlocomotion (Fi,go=20.54, p Åq O.OOI vs. Saline-METH). There were no significant differences
between the ISt and 5th administration in NPC-15437-treated mice.
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Discussion
  In the present study, I observed morphological changes in astrocytes by treatment
with either METH or MRP in cortical neuronlglia co-cultures. A difference was noted
between the effects of METH and MRP in purified cortical astrocytes: while METH
markedly activated astrocytes with phosphorylation of PKC, MRP had no such effect.
  I also found that treatment with METH (10 vM) for 3 days increased the sensitivity
of cortical astrocytes to dopamine and glutamate, which can be responsible for
rewarding effects of psychostimulants and opioids69' 70). Many lines of evidence
support the idea that the enhanced Ca2' signaling in astrocytes is not only restricted to
single cells, but also can cross cell borders via gap junctions, resulting in intracellular
Ca2' waves traveling from one astrocyte to another, and the induction of Ca2' responses
                                .s
in neuronsi3'7i). Taken together, these findings suggest that treatment with METH may
cause the functional up-regulation of neuroactive substances in astrocytes. It is also
likely that the increase in astrocytic Ca2' signaling induced by dopamine and glutamate
following chronic exposure to METH may result from an enhancement of astrocytic
dopamine and glutamate receptor functions induced by METH.
  A study of cultures of newborn rodent CNS cells has shown that heterogeneous
subpopulations of astrocytes can express one or more types of opioid receptor72' 73). It
has been reported that preferential pt-opioid receptor agonists can interfere with
neuronal cell division'`). In the present study, I found that the pt-opioid receptor
agonist MRP had no effect on astrocytic activation in purified cortical astrocytes,
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whereas it caused astrocytic activation in cortical neuron/glia co--cultures. These
findings constitute evidence that MRP might activate astrocytes via neurons.
Furthermore, the present results raise the possibility that METH and MRP may
differentially regulate long-term changes in neuron-glia communication.
  Here I demonstrated that the astrocytic activation in cortical neuron/glia co-cultures
induced by either METH or MRP was blocked by treatment with a specific PKC
inhibitor. Several lines of evidence have suggested that neurite outgrowth on several
cell adhesion and matrix moleculesi9' 52), including fibronectin75), laminin and collagen'6),
are reduced by the specific inhibition of PKC, suggesting that PKC plays an important
role in regulating the direction of neurite growth. These findings, along with those in
the present study, suggest that PKC is likely to be one of the most important factors in
modulating the synaptic plasticity induced by METH and MRP.
   I also found the difference between METH and MRP in the maintenance of
astrocytic activation: METH produced prolonged astrocytic activation, whereas MRP
caused a reversible activation of astrocytes in cortical neuron/glia co-cultures.
Astrocytic activation has been considered for a long time as the major impediment to
axonal regrowth after an injury in the CNS26' 2D. However, there are increasing
evidences that astrocytes play a dynamic role in regulating synaptic strength,
syRaptogenesis and neurogenesis2022). Although the exact function of METH- and
MRP-induced astrocytic activation remains unclear at this time, it may positively
modulate synaptic activity by directly controlling synaptic strength, leading to synaptic
plasticity in the CNS.
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  Cultured cells used in the present in vitro study represents a simplified relative to the
state of neuron-glia communication in the CNS. Thus, additional interactions with
these cells and matrix components in in vivo system are likely to reflect the behavioral
change such as behavioral sensitization. In fact, one of the most important aspects of
the present study was that the METH-induced behavioral sensitization was maintained
even after a long period of abstinence, while the MRP-induced sensitization was
reversible. This may be consistent with the evidence that METH, but not MRP,
produced long--lasting astrocytic activation in cortical neuronlglia co-cultures. It is,
therefore, worthwhile in future studies to identify the precise molecular steps associated
with astrocyte-to-neuron signaling on a long-lasting maintenance of METH-induced
behavioral sensitization.
  Another key finding of the present study was that the levels of GFAP in the mouse
CG and N.Acc. were clearly increased by repeated in vivo administration of METH,
which was related to behavioral sensitization. These results suggest the repeated in
vivo treatment of METH could produce the actiyation of astrocytes in the CG and
N.Acc. Central dopamine systems have been implicated in mediating reward-related
behaviors4i-`3). In particular, the N.Acc. of the mesolimbic dopamine pathway plays an
important role in regulating the rewarding effects of many stimuli including drugs of
abuse"i-"3). It has been also recognized that the CG is responsibie for stimulus-reward
learning77). Taken together, these studies suggest the possibility that METH-induced
astrocytic activation in these areas modulates the development of METH-induced
behavioral sensitization.
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  The development of behavioral sensitization to METH with astrocytic activation was
abolished by co-treatment with the PKC inhibitor NPC15437. Although further
experiment is still required, these findings indicate that activated PKC-dependent
astrocytic response in the CG and N.Acc. by intermittent METH treatment may be
implicated in the development of sensitization to the METH-induced hyperlocomotion.
  Finally, I investigated the neurotoxic effects of METH and MRP: METH markedly
induced neuronal cell death in cortical neuron/glia co-cultures, while MRP had no such
effect. Glial activation is thought to be neuroprotective2628), howeyer, excess activation
can be deleterious in the brain28' '8). In fact, overexpression of astrocyte-derived
neurotrophic protein S100P has been shown to induce neuronal cell death through nitric
oxide released from astrocytes79). Taken together, the present findings support the idea
that the direct effect induced by high concentration of METH on astrocytes may lead to
a dynamic change in neuron-glia network, resulting in the neurotoxicity.
  In conclusion, the present data clearly provide direct evidence for the distinct
mechanisms between METH and MRP on the astrocytic and neuronal responses.
Nevertheless opioids, such as MRP, have been used worldwide to control chronic pain,
the appearance of opioid addiction following chronic administration of opioids seriously
limits their use for the relief of moderate to severe pain. The information of the
reversibility of astrocytic response and behavioral sensitization with no neuronal cell
death induced by MRP could break through the definition of "opioid addiction" and the
misleading of concept that MRP is dangerous. Furthermore, the long-lasting
maiRtenance of behavioral sensitization to METH and neuronal cell death by high
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concentration of METH observed in this study strongly
risk of the psychostimulant use in humans.
support the idea for the high
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Chapter 2
Glutamatergic neurotransmission and protein kinase C play a
role in neuron-glia communication during the development of
the rewarding effect induced by methamphetamine
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                             Introduction
  It has been established that astrocytes respond to the synaptic release of various
neurotransmitters6LiO), such as glutamate and ATR which often leads to the transient
elevation of [Ca2']i4' i3' i4). The Ca2' response, and the subsequent activation of various
signaling pathway, regulate the release of various signaling molecules from astrocytes`).
Therefore, both neuron-to-astrocyte and astrocyte-to-neuron signaling pathways are
integral units which serve multiple and diverse roles in the CNS.
  On the other hand, long-lasting synaptic adaptations in dopaminergic andlor
glutamatergic neurotransmission provide a neuronal framework for altered behavioral
processing which underlies the development of psychological dependence on drugs of
abuse39-4i). As described in Chapter 1, I found that in vitro treatment of mouse cortical
neuron/glia co-cultures with drugs of abuse, such as METH and MRP, caused
morphological changes in astrocytes via PKC. I also found that treatment with METH
increased the sensitiyity of astrocytes to glutamate and dopamine. These findings
indicate that astrocytes play an important role in the dependence producing of drugs of
abuse. However, the exact function of astrocytic changes induced by drugs of abuse
remains unclear.
  The purpose of the present study was to clarify the role of glutamatergic
neurotransmission and its association with PKC in METH-induced functional andlor
morphological changes in astrocytes using cortical neuron!glia co-cultures. I also
examined the effects of glutamate receptor antagonists on the activation of astrocytes
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and the development of the rewarding effect induced by METH.
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Materials and methods
Tissue Processing
  Tissue processing was conducted as previously described in Chapter 1.
Drug treatment and immunohistochemistry
  At day 7 in vitro, the cells were treated with either normal medium, METH (10 pM),
a selective NR2B subunit-containing N-methyl-D-aspartate (NMDA) receptor
antagonist 2-(4-benzylpiperidino)-1-(4-hydroxyphenyl)-1-propanol hamitartrate
(ifenprodil hemitartrate: 1-10 ptM, Grelan Pharmacol. Co. Ltd., Tokyo, Japan) + METH,
an ct-amino-3-hydroxy-5-methylisoxazole4-propionic acid (AMPA) receptor antagonist
6,7-dinitroquinoxaline-2,3-dione (DNQX, 1-10 ptM, Acros Organics One Reagent Lane,
Fairlawn, NJ, USA) + METH or a metabotropic glutamate receptor 5 (mGluR5)
antagonist 2-methyl-6-(phenylethynyl)-pyridine hydrochloride (MPEP, 1-10 ptM,
Sigma-Aldrich Co.) + METH for 1 day. Other cells were treated with glutamate (1-
100 nM, Wako Pure Chemicals Ind., Ltd.), a selective PKC inhibitor CHE (10nM,) +
glutamate, a PKC activator phorbol 12, 13-dibutyrate (PDBu: 1-100 nM, Sigma-Aldrich
Co.) or PDBu + CHE for 1 day. The cells were then identjfied by immunofluorescence
using a mouse polyclonal antibody to neuronal nuclei (NeuN, 1:1000: Chemicon
International Inc.), a mouse polyclonal antibody to GFAP (1:1000) or a rabbit
polyclonal antibody to p-PKC (1:400) followed by incubation with Alexa 488-
conjugated goat anti-mouse IgG (1:4000; for GFAP and NeuN) or Alexa 546-conjugated
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goat anti-rabbit IgG (1:40oo; for p-PKC). Images were collected using a Radiance
2000 laser-scanning microscope (Radiance 2ooO). The experiments were repeatedly
performed by, at least, 3 independent culture preparations
 The measurement of GFAP-like immunoreactivity was conducted as previously
described in Chapter 1.
Confocal Ca2' imaging
  The experiment involving confocal Ca2' imaging was performed following the
method described in Chapter 1.
  Glutamate (10 ptM) or PDBu (100 nM) was perfused for 30 sec at 5 mL/min at room
temperature in cultured cortical neurons or astrocytes, followed by superfusion of BSS.
Either CHE (1 ptM), a calciumlcalmodulin-dependent protein kinase II (CaMKII)
inhibitor 2-tN-(2-hydroxythyl)-N-(4-methoxy-benzenesulfonyl)]amino-N-(4-
chlorocinnamyl)-N--methylbensylamine (KN-93, 10 pM, Calbiochem-Novabichem Co.,
CA, USA) or a PLC iBhibitor 1-(6-[([17P]-3-methoxyestra-1,3,5[10]-trien-17-yl)-IH-
pyrrole-2,-dione (U73122, 5 pM, Sigma-Ardrich Co.) was incubated 10 min before
glutamate (10 ptM) or PDBu (100 nM) treatment.
Place conditioning
   Male ICR mice weighting 25-30 g were obtained from Tokyo Laboratory Animals
Science Co. (Tokyo, Japan). Animals were housed in a room maintained at 23 Å} 1 eC
with a 12 hr light-dark cycle. Food and water were available ad libitum.
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  Place conditioning studiesS" 80) were conducted using apparatus consisting of a shuttle
box (15 x 30 x 15 cm, w x I x h), which was made of acryljc resin board and djyided
into two equal-sized compartments. One compartment was white with a textured floor
and the other was black with a smooth fioor to create equally inviting compartments.
The conditioned place preference schedule consisted of the three phases (pre-
conditioning test, conditioning and post-conditioning test). The pre-conditioning test
was performed as follows: the partition separating the two compartments was raised to 7
cm above the floor, a naturai platform was inserted along the seam separating the
compartments, and mice that had not been treated with either drugs or saline were then
placed on the platform. The time spent in each compartment during 900-sec session
was then recorded automatically using an infrared beam sensor (KN-80, Natsume
Seisakusyo Co. Ltd., Tokyo, Japan).
  Conditioning sessions were started after s.c. injection of either METH (1 mglkg) or
saline; these animals were placed in the compartment opposite that, in which they had
spent the most time in the pre-conditioning test, for 1 hr. On alternate days, these
animals received with saline and were placed in the other compartment for 1 hr.
Intracerebroventricular (i.c.v.) administration of either vehicle, ifenprodil (10
nmollmouse), DNQX (30 nmollmouse) or MPEP (100 nmol/mouse) was performed 30
min before s.c. treatment with METH (1 mglkg, s.c.) or saline. On the day after the
final conditioning session, these animals were placed in the test apparatus without any
confinements, and then the relative amount of time spent in these compartments was
measured (post-conditioning). The preference for drug-paired place was shown as
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mean difference between time spent during the post--conditioning and pre-conditioning
tests.
Statistical analysis
  The data of confocal Ca2' imaging and GFAP-like immunoreactivity are presented as
the mean Å} SEM. The statistical significance of differences between the groups were
assessed by one-way ANOVA with Student's t-test.
  Conditioning scores for each mouse are obtained by subtracting the cumulative time
(sec) spent in the saline-paired side from that in the METH-paired side, are expressed as
means Å} SEM. A statistical analysis for place conditioning study was performed using
one-way ANOVA followed by Bonferroni/Dunnett's test.
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Results
Tbeatment with METH induced the phosphorylation of both neuronal and
astrocytic PKC in cortical neuron/glia ce-cultures
  Immunohistochemical staining with an antibody to p-PKC confirmed that treatment
with METH (10 pM, 3 days) increased the immunoreactivity of p-PKC in both neurons
and astrocytes (Figure 2-IA, B), indicating that PKC may be involved in this event.
  To ascertain whether the direct activation of PKC could induce any morphological
changes, the selective PKC activator PDBu was applied to cortical neuron/glia co-
cultures. Treatment with PDBu (10, 100 nM) for 24 hr induced a robust activation of
astrocytes, as detected by a stellated morphology and an increase in the level of GFAP-
like immunoreactivity in cortical neuron/glia co-cultures (p Åq O.OOI vs. control cells,
Figure 2-2A, B). This astrocytic activation was abolished by co-treatment with CHE
(10 nM, p Åq O.Ol vs. PDBu-treated cells, Figure 2-2A,B). Treatment with glutamate
(10, 100 nM) for 24 hr also induced a robust activation of astrocytes in mouse cortical
neuron/glia co-cultures (p Åq O.05, p Åq O.OOI ys. control cells, Figure 2-2A, C), and this
activation of astrocytes was reversed by treatment with the PKC inhibitor CHE (10 nM,
p Åq O.OOI vs. glutamate-treated cells, Figure 2-2A, C).
Role of PKC in glutamate-induced Ca2' response in neurons
  To study the PKC-dependent glutamate response in mouse cortical neuron/glia co-
cultures, I performed Ca2' imaging experiments. Glutamate (10 pM, 30 sec) produced
                                 ua
a transient increase in [Ca2']i in cultured conical neurons (Figure 2-3A, B). The Ca2'
response to glutamate was dramatically and significantly abolished by pretreatment with
CHE (1 ptM: p ÅqO.OOI vs. glutamate 10 ptM, Figure 2-3A, B). In addition, this Ca2'
response was also significantly abolished by pretreatment with the CaMKII inhibitor
NK-93 (10 ptM: p Åq O.OOI vs. glutamate 10 ptM, Figure 2-3A, B) and the PLC inhibitor
U73122 (5 pM: p Åq O.OOI vs. glutamate 10 ptM, Figure 2-3A, B). The direct activation
of PKC induced by PDBu (100 nM, 30 sec) also produced a transient increase in [Ca2'li
in cultured cortical neurons, and this Ca2' response was significantly prevented by
pretreatment with either CHE (1 ptM: p Åq O.OOI vs. PDBu 100 nM, Figure 2-3C, D) or
KN-93 (10 ptM: p Åq O.Ol vs. PDBu 100 nM, Figure 2-3C, D). However, unlike
glutamate-induced Ca2"responses, pretreatment with U73122 (5 ptM) failed to attenuate
the PDBu-induced Ca2' responses in cultured conical neurons (Figure 2-3C, D).
  I next tried to investigate the role of PKC in glutamate-induced Ca2' responses in
purified cortical astrocytes. Glutamate (10 ptM, 30 sec) produced a transient increase
in tCa2']i in purified cortical astrocytes (Figure 2-4A, B). Similar to the glutamate-
induced Ca2' response in neurons, pretreatment with both CHE (1 ptM) and U73i22 (5
ptM) significantly abolished the glutamate-induced Ca2' responses in purified cortical
astrocytes (p Åq O.OOI vs. glutamate 10 ptM, Figure 2-4A, B). However, KN-93 (10
ptM) failed to block the glutamate-induced increase in Ca2' in purified cortical
astrocytes (Figure 2-4A, B). PDBu (100 nM, 30 sec) also produced a transient
increase in (Ca2']i in purified cortical astrocytes (Figure 2-4C, D). This event was
completely blocked by CHE (1 ptM: p Åq O.OOI vs. PDBu 100 nM, Figure 2-4C, D).
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Unlike PDBu-induced Ca2' responses in neurons, both KN-93 (10 ptM) and U73122 (5
ptM) failed to affect the PDBu-induced Ca2' responses in purified cortical astrocytes
(Figure 2-4C, D).
Enhancement of the glutamate-induced Ca2' response by PDBu
  I next investigated whether the activation of PKC could induce any functional
changes in neurons or astrocytes. PDBu (10 nM, 30 sec) itself failed to induce Ca2'
responses in both cortical neurons (Figure 2-5A) and astrocytes (Figure 2-5A, B).
Since a long-term treatment with PDBu has been known to induce the down-regulation
of PKC, I applied a low concentration of PDBu (10 nM) to cells and then treated them
with glutamate or dopamine to estimate the effect of PKC activation. The Ca2'
response to glutamate (1 ptM) was significantly enhanced by co-treatment with PDBu
(10 nM) in both cultured mouse cortical neurons and astrocytes (p Åq O.OOI vs. control
cells, Figure 2--5A, B). The Ca2' response to glutamate (1-10 ptM) was also enhanced
by co-treatment with PDBu (10 ptM) in purified conical astrocytes (p Åq O.OO1, Figure 2-
5B). On the other hand, co-treatment with PDBu (IO nM) failed to affect the
dopamine (1-10 ptM)-induced Ca2' responses in both neurons and astrocytes.
Enhancement of the glutamate-induced Ca2' response by METH
  METH (10-100 ptM, 30 sec) itself failed to induce Ca2' responses in cultured cortical
neurons (Figure 2-6A). However, the glutamate (1-100 ptM, 30 sec)-induced Ca2'
responses in neurons were significantiy enhanced by treatment with METH (10 ptM, 3
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days, pÅq O.OOI vs. control ceHs for 1-10 ptM glutamate, pÅq O.Ol vs. control cells for
100 ptM glutamate, Figure 2-6B, C). Unlike glutamate-induced Ca2' responses in
neurons, treatment with METH (1O pM, 3 days) failed to enhance the dopamine (1, 100
pM, 30 sec)-induced Ca2' responses in neurons (Figure 2-6D). Although the dopamine
(10 pM, 30 sec)--induced Ca2' responses in neurons were significantly enhanced by
treatment with METH (10 ptM, 3 days, p Åq O.05 vs. control cells, Figure 2-6D), the
potency of enhancement was weaker than that of glutamate-induced Ca2' responses.
Role of glutamatergic transmission in the activation of astrocytes induced by
METH.
  The activation of astrocytes induced by METH (10 ptM, 3 days) was completely
reversed by co-treatment with the specific NMDA receptor NR2B subunit antagonist
ifenprodil (1-10 ptM, p Åq O.OOI vs. METH treated cells, Figure 2-7A, B) and the
mGluR5 antagonist MPEP (1-10 pM, p Åq O.OOI vs. METH treated cells, Figure 2-7A,
B) in cortical neuronlglia co-cultures. This activation of astrocytes was partially
reversed by co-treatment with the specific AMPA receptor antagonist DNQX (1-10 ptM,
p Åq O.Ol, p Åq O.OOI vs. control cells, p Åq O.OOI vs. METH-treated cells, Figure 2-7A, B)
in cortical neuronlglia co-cultures. Under these conditions, each of the glutamate
receptor antagonists (I-IO yM, 3 days) failed to affect the GFAP-like immunoreactivity
in cortical neuronlglia co-cultures (data not shown).
Role of glutamatergic transmission in the rewarding effect induced by METH.
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  Finally, I ascertained the effects of glutamate receptor antagonists on the rewarding
effect of METH in mice. It was previously reported that chronic in vivo treatment with
METH produced a significant dose-dependent preference for the drug-associated place
in the conditioned place preference paradigm53). In the present study, Ifound that the
place preference produced by chronic administration of METH (1 mglkg, s.c.) was
significantly suppressed by i.c.v. pretreatment with either ifenprodil (10 nmol/mouse,
174.9 Å} 33.4 sec for vehicle-METH group, 63.9 Å} 27.2 sec for ifenprodil-MEHT group;
"" p Åq O.Ol vs. vehicle-METH group, Figure 2-8A), DNQX (30 nmoSlmouse, 142.7 Å}
11.7 sec for vehicle-METH group, 25.6 Å} 25.9 sec for DNQX-METH group; #""p Åq
O.OOI vs. vehicie-METH group, Figure 2-8B) or MPEP (100 nmollmouse, 156.9 Å} 1l.9
sec for yehicle-METH group, 72.1 Å} 33.0 sec for MPEP-METH group; ""p Åq O.Ol vs.
vehicle-METH group, Figure 2-8C).
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In cortical neuronlÅí.T.lia co-cultures
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Figure 2-1 Treattnent xvith PvlETH (10 yL)`ib t'or 3 clay: caused astrocytie activation associatecl
xvith phosphor.vlation of prote'in kina:e C {PKC) in coitieal neuronfglin uo-culturc:'. (A)The red
labe] for p-PK(J staincd ",ith a rabbit polÅr'elonal antibodÅr, and the .grccn labcl t'orCJF,iXPsrainecl
"•'ith mouse 1)olÅr-c]on;" antibodÅr., are coloca)ized in coilic,al neuron!LaliiL co-cullurc-: . {BÅrThe .g reen
labcl forl eu-N stalned Nvith a mouse polÅr'clonal imtib(xl.N and thc red label ibr p-PKC :'tained xvith
a rabbit pc)lÅr•'clonal antibÅqxtÅr' show cok}c'alization in coilical ncttron!ta]ia eo-cujture:h.
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In cultured cortical neurons
(A)
Glutamate(10pM)
  -
+CHE
(1 uM, 10 min)
l•i=L
   1OO sec
+ KN-93
(10 pM, 10 min)
+U73I22
(5 uM. 10 min)
(B)
oTe
=
-
=
't(
1.5
1.0
O.5
o
*kk
+ CHE
***
+ KN93
*ik*
+ U73 1 22
Glutamate (lO pM, 30 sec)
I'DBu (1OO nM)
  ww(C)
+CHE
(1 uM. 10 min)
ll
1
lt
+ KN-93
(10 LtM, 10 min)
+U73122
(5 yM. 10 min)
(D)
  1,5
ove
=nE
Åq
1.0
O.5
o
**k
+CHE + KN93 + U73122
PDBu(100 nM, 30 sec)
Figure 2-3 Characterization of the glutamate- and PDBu-induced increase in intracel]u]ar Cai'
concentration ICa2'li in cultured cortical neurons. (A) Traces show the glutamate (10 ptM, 30 sec)-
evoked increase in ICa2'li in mouse cortical neurons with or without the PKC inhibitor CHE (1 ptM),
the CaMKII inhibitor KN93. (10 ptM) or thePLC inhibitor U73]22 (5 geTvD. Cells w• ere pretreatedwith
these inhibitors for 10 min prior to glutamate (10 pM) application. (B) The Ca2' responses to
glutamate in neurons are summarized. Data represent the mean Å} SEM of .54-72 cells. **pÅq O.O].
'** p Åq O.oo1 vs. glutamate (10 ItM)-treated cells. (C) Traces show the PDBu (IOO nM, 30 sec)-
evoked increase in [Ca2'li in neurons with or Nvithout CHE (1 uM), KN93 (10 yM) or U73. 122 (5
yM), Cells were thenpretrcated with these inhibitors for 1O min prior to PDBu (1OO nM) application.
(D) The Ca2' responses to PDBu in neurons are summarized. Data represent the mean Å} SEM of 63-
72 cel ls. '*p Åq O.O1, ""p Åq O. oo 1 vs. PDBu (1 oo nM)-treated cells.
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In purified cortical astrocytes
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Figure. 2-4 Characterization of the .g.lutamate- and PDBu-induced increase in intracellular Ca2"
conccntration ([Ca2'li) in puri fied cortica] astK)cytes, 1'races shoNv the glutamate (1 O IuM, 30 sec)-evoked
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Figure 2-)' Enhancement of Ca2' responses to glutamate by the PKC activator PDBu in both mouse
cortical neurons and astrocytes, PDBu (IO nM 30 sec. open columns) itself t"ailed to induce Ca2'
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                              Discussion
  It has been reported that PKC contributes to the direction of neurite growth in celi
adhesion'9' 52). PKC could also regulate the morphology of astrocytes78' 8i). I
confirmed here that the direct activation of PKC by PDBu caused a robust activation of
astrocytes. In vitro treatment with glutamate also caused PKC-dependent astrocytic
activation. The key finding of the present study was that in vitro treatment with
METH enhanced the giutamate-induced Ca2" response in neurons. Furthermore, in
vitro treatment of cortical neuronlglia co-cultures with METH caused the
phosphorylation of PKC in both neurons and astrocytes. It should be noted that
treatment with METH caused morphological stellation and an increase in the levels of
GFAP in astrocytes.
  Activated astrocytes are thought to differ from non-activated astrocytes with respect
to their ability to adjacent neurons from excitotoxicity2`). Several studies have shown
that neuronal excitotoxicity is associated with excess activation of astrocytes26' 82).
Astrocytic activation could contribute to deterioration in conditions of chronic
neurodegeneration, hence activated astrocytes secrete nitric oxide and inflammatory
cytokines, and exert strong neurotoxic effects26). On the other hand, astrocytic
activation could counteract the neuroprotectiye effect of astrocyte-derived growth
factors83' 84). Thus, activation of astrocytes may affect the neuronal environment,
resulting in synaptic plasticity in the CNS. Taken together, the present findings
suggest that the changes induced by METH may regulate neural circuits during the
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development of psychological dependence on METH.
  Neurons and astrocytes respond to various electrical and chemical stimuli, including
neurotransmitters, neuromodulators and hormones, with an increase in ICa2' ]i. These
Ca2' responses result from the coordinated activity of several molecular cascades
responsible for Ca2' movement into or out to the cytoplasm by way of either the
extracellular space or intracellular stores. On the other hand, PKC activity is
stimulated by a rise in [Ca2' ]i. In the present study, the specific PKC inhibitor CHE
produced a dramatic suppression of the glutamate-induced Ca2' responses in both
neurons and astrocytes. Direct activation of PKC by PDBu also produced transient
Ca2' responses in both neurons and astrocytes. Conversely, co-treatment with a low
concentration of the PKC activator PDBu clearly enhanced the glutamate-induced Ca2'
responses in both neurons and astrocytes. Thus, the present data suggest that PKC is
involved in glutamatergic neurotransmission in the CNS.
  CaMKII is a ubiquitously expressed protein kinase that transduces the elevated Ca2'
signals in cells to several target proteins ranging from ion channels to transcriptional
activators. It has been reported that the activation of CaMKII induces phosphorylation
of the carboxy-terminal region of the NR2B subunit of NMDA receptors85). In my
preliminary study, I found that a nonselective NMDA receptor antagonist MK-801
(disocylpine) and the selective NR2B subunit-containing NMDA receptor antagonist
ifenprodil abolished the glutamate-induced Ca2' responses in cultured cortical neurons86).
In the present study, the CaMKII inhibitor KN93 also produced a dramatic suppression
of the glutamate-induced Ca2' response in neurons. Thus, the present findings suggest
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that the activity of CaMKII, as well as PKC, may contribute to the positive regulation of
glutamatergic signaling presumably through the NR2B subunjt of NMDA receptors in
neurons.
  CaMKII-dependent glutamatergic Ca2' signaling may be responsible for the
development and/or expression of rewarding effects induced by drugs of abuse. In fact,
it has been already reported that the MRP-induced rewarding effect was significantly
suppressed by treatment with KN-938D, suggesting that activated CaMKII plays a
substantial role in the development of MRP-induced rewarding effects.
  Recent reports have stated that there are three mammalian PI-PLC isoform families:
PLCP, PLCy and PLC65'). All known forms of PKCP (Pl-P4) are stimulated to
various extents by the G,m. family. On the other hand, mGlu5 receptor is physically
linked to the NR2B subunit of NMDA receptors88). mGluR5 receptors coupling to
Gq/ii.89' oo) could stimulate PLC6-isozyme, which generate diacylglycerol and inositol
triphosphate, leading to the activation of PKC and Ca2' mobilization, respectively. In
the present study, I found that the PLC inhibitor U73122 completely blocked the
glutamate-induced Ca2' response in neurons. Therefore, it seems likely that U73122
could affect metabotropic receptor-coupled G,,,,./PLCP signaling. The present data
suggest that the functional interaction between mGluRs and NMDA receptors could
involve the expression of PKC/CaMKII-dependent glutamate-induced intracellular
signaling in neurons.
  mGluRs, but not NMDA receptors, are ordinarily expressed in astrocytes`' 6-8' '8). In
fact, I previously confirmed that the selective mGIuR5 receptor antagonist MPEP
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clearly blocked the glutamate-induced Ca2' responses in astrocytes, whereas either MK-
801 or ifenprodil failed to block this phenomenon86). In the present study, Ifound that
CHE and U73122, but not KN93, completely blocked the glutamate-induced Ca2'
responses in astrocytes. Considering these observations, it seems likely that glutamate
affects the coupling of mGluR receptors to Gq/ii., stimulate PLCP-isozyme, and thus
leads to Ca2' responses in astrocytes.
  In contrast, a low concentration of PDBu failed to affect the dopamine-induced Ca2'
responses in neurons and astrocytes. Although the various actions of dopamine are
mediated by five different receptor subtypes, which are members of the large G-
protein-coupled family, none of these dopamine receptors are coupled with G,m or any
ion channels. Thus, these results seem to indicate that PKC may not be critical for
dopaminergic neurotransmission in cortical cultures.
  Notably, treatment with METH (10 ptM) for 3 days increased the sensitivity of
cortical neurons to glutamate, indicating that treatment with METH may cause the
functional up-regulation of glutamatergic neurotransmission. As mentioned above,
treatment with METH caused a robust phosphorylation of PKC, which could regulate
the glutamate-induced Ca2' responses in neurons and astrocytes. Collectively, the
enhancement of PKC-dependent Ca2' responses to glutamate induced by METH could
lead to an increase in the excitability of the CNS, resulting in the development of
synaptic changes induced by METH.
  Moreover, the activation of astrocytes induced by METH (10 pM) for 3 days was
dramatically diminished by treatment with either ifenprodil, the AMPA receptor
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antagonist DNQX or MPEP. These findings raise the possibility that METH activates
astrocytes through glutamatergic transmission. Activated astrocytes may regulate
synaptic transmission by the release of glutamate or the uptake of glutamate from the
synaptic cleft via membrane transporters. In Chapter 1, I demonstrated that the
glutamate-induced Ca2' responses in astrocytes were significantly enhanced by 3 days
of treatment with METH (10 ptM). Activated astrocytes may, at least in part, potentiate
glutamatergic neurotransmission, leading to the development and/or expression of the
rewarding effects by METH.
  Several lines of evidence suggest that glutamatergic projections to the N.Acc.
originating from the prefrontal cortex, hippocampus and amygdala regulate emotional
and behavioral processing`5). Therefore, I confirmed the role of glutamatergic
neurotransmission during the development of the rewarding effect induced by METH.
The place preference produced by repeated in vivo administration of METH was
significantly suppressed by i.c.v. treatment with either ifenprodil, DNQX or MPEP.
These findings suggest that the activation of glutamatergic neurotransmission is
necessary for the development andlor expression of the rewarding effects induced by
METH. The activation of NMDA receptor, AMPA receptor and mGluR5 may regulate
each other in the development of the rewarding effect induced by METH.
  In summary, I demonstrated here that PKC plays a positive regulatory role in the
ayailability of Ca2' signaling in response to glutamate in both neurons and astrocytes.
On the other hand, CaMKII, which modulates the development andlor expression of the
rewarding effects induced by psychostimulants, also has the ability to modulate
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glutamatergic transmission in neurons, but not in astrocytes. METH could ifiduce
PKC-dependent astrocytic actjvatjon through glutamatergic transmission. PKC--
dependent glutamatergic transmission in both neurons and astrocytes may, at least in
part, modulate the expression of the rewarding effect of METH. These findings raise
the fascinating possibility that METH-induced dynamic changes in PKC-dependent
communication between neurons and astrocytes may be associated with glutamatergic
synaptic plasticity.
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Chapter 3
Direct evidence of astrocytic modulation in the development
of rewarding effects induced by drugs of abuse
63
                             Introduction
  As described in chapter l and 2, two-way communication between neurons and glial
cells is essential for axonal conduction and synaptic transmission. It has been widely
accepted that long-term exposure to psychostimulants induces neuronal plasticity3`38).
Accumulating evidence suggests that astrocytes may also actively participate in synaptic
plasticity39-4i).
  It has been documented that repeated amphetamine treatment results in the increased
astrocytic expression of basic fibroblast growth factor, which is necessary for the
development of sensitization to amphetamine9'). It has been also reported that the
expressjon of GFAP-positive astrocytes expression is increased in the VTA and
hippocampus following relatively short-term withdrawal subsequent to cocaine
exposure92). In Chapter 1, I described that the levels of GFAP in the mouse N.Acc. and
CG were clearly increased by chronic in vivo administration of METH. These data
raise the possibility that astrocytes contribute to the synaptic plasticity during the
development of rewarding effects induced by psychostimulants. However, little is
known about direct action of astrocytes on the development of rewarding effects
induced by drugs of abuse.
  The present study was then undertaken to clarify the role of astrocytes during the
development of rewarding effects induced by METH and MRP.
M
Materials and Methods
Tissue Processing
  Preparation of purified conical astrocytes was performed following the method
described in Chapter 1.
  To prepare astrocyte-conditioned medium (ACM), purified cortical astrocytes were
grown to confluence. Cells were washed once with DMEM and then covered with an
equal volume of serum-free medium for 24 hr at 37 eC and 5 9o C02 in the presence of
the indicated treatments. The supernatant was collected 1 day after changing to serum-
free medium culture and centrifuged for 20 min at 1,Ooo x g. The final supematant
was used as ACM.
  Purified cortical microglia were grown as follows; cerebral cortices were obtained
from newborn ICR mice (Tokyo Laboratory Animals Co., Ltd.), minced, and treated
with trypsin (O.025 9o, Invitrogen Co.) dissolved in PBS solution containing O.02 9o L-
cysteine (Sigma-Aldrich Co.) monohydrate, O.5 9o glucose (Wako Pure Chemicals Ind.,
Ltd.) and O.02 9o bovine serum albumin (Wako Pure Chemicals Ind., Ltd.). After
enzyme treatment at 37 "C for 15 min, cells were dispersed by gentle agitation through a
pipette and plated on a flask with DMEM supplemented with 5 9e IBS, 5 9o HS, 10
U/mL penicillin and 10 geg/mL streptomycin in a humidified atmosphere of 95 % air and
5 9o CO, at 37 eC. The cultured medium was exchanged to new medium every 3 days.
About 9 days after seeding, the flask was shaken for 2 min to remove microglia. A cell
suspension were collected and centrifuged (20 min, 3,OOO x g). The cells were seeded
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at a density of 1 x 105 cells/cm3. The cells were maintained for 3 days in DMEM
supplemented with 5 9o FBS, 5 9o HS, 10 U/mL penicillin and 10 pg/mL streptomycin
in a humidified atmosphere of 95 9o air and 5 9o C02 at 37 OC.
  To prepare microglia-conditioned medium (MCM), purified cortical microglia were
grown to confluence. Cells were washed once with DMEM and then covered with an
equal volume of serum-free medium for 24 hr at 37 OC and 5 9o C02 in the presence of
the indicated treatments. The supernatant was collected 1 day after changing to the
serum-free medium culture and centrifuged (20 min, 3,OOO x g). The final supernatant
was used as MCM.
  Preparation of cortical neuronlglia co-cultures was performed following the method
described in Chapter 1.
Drug treatment and immunohistochemistry
  Mouse cortical neuron/glia co-cultures were treated with either normal medium,
METH (10 ptM), METH + a glial modulator 3-methyl-1-(5-oxohexyl)-7-propylxanthine
(propentofylline: PPF, 1-3 pM, Sigma-Aldrich Co.), MRP (10 ptM) or MRP (10 ptM) +
PPF (1-3 pM) for 3 days. To explore the effect of astrocyte-released soluble factors,
mouse purified cortical astrocytes were treated with either DMEM, ACM, ACM
collected from METH (10, 1oo pM, 3 days)-treated astrocytes (METH 10 pM-ACM,
METH 100 ptM-ACM) or ACM collected from MRP (10, 1oo pM, 3 days)-treated
astrocytes (MRP 10 ptM-ACM, MRP 1oo pM-ACM) for 1 day. Mouse purified
conical microglia were treated with either normal medium, METH (1-1oo pM) or MRP
                                 66
(1-1oo ptM) for 3 days. The cells were then identified by immunofluorescence using a
mouse antibody to GFAP (1:1000) or a rat antibody to OX42 (1:250, Serotec Ltd.,
Oxford, UK) followed by incubation with Alexa 488-conjugated goat anti-mouse IgG
(1:4000 for GFAP) or with Alexa 488-conjugated goat anti--rat IgG (1:4000 for OX42).
Images were collected using a Radiance 2000 laser-scanning microscope. The
experiments were repeatedly performed by, at least, 3 independent culture preparations.
  The measurement of GFAP-like immunoreacivity was conducted as previously
described in Chapter 1.
Surgery and microinjection
  Male ICR mice weighing 25-3e g were obtained from Tokyo Laboratory Animals
Science Co. Animals were housed in a room maintained at 23 Å} 1 OC with a 12 hr
light-dark cycle. Food and water were available ad libitum.
  After 3 days of habituation to the main animal colony, all mice were anesthetized
with sodium pentobarbital (70 mg/kg, i.p.). The anesthetized animals were placed in a
stereotaxic apparatus (Kopf Ins., Tujanga, CA, USA). The skull was exposed and a
small hole was made using a dental drill. An infusion cannula (D-1-6-02, Eicom Co.,
Kyoto, Japan) was positioned into the N.Acc. (from bregma: anterior +1.5 mm, lateral -
O.9 mm, ventral -4.6 mm), CG (from bregma: anterior +1.0 mm, lateral -O.3 mm, ventral
-
1.4 mm) or corpus striatum (CPu: from bregma: +1.5 mm, lateral -1.3 mm, ventral -3.5
mm) according to the atlas of Paxinos and Franklin93). The animals were injected with
either DMEM, ACM, ACM + a Janus tyrosine kinase/signal transducers of activated
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transcription (Jak/STAT) inhibitor a-cyano-(3,4-dihydroxy)-N-benzylcinnamide
(AG490, O.1 nmol, Calbiochem-Novabiochem, La Jolla, CA, USA), DMEM-AG490
(O.1 nmol), METH 10 ptM-ACM or MCM in a volume of 100 nLlmouse into the N.Acc.
via the infusion cannula using a Hamilton syringe at an infusion rate of 10 nLlmin.
Other groups of animals were injected with DMEM or ACM in a volume of 100
nLlmouse into the CG or CPu via the infusion cannula using a Hamilton syringe at an
infusion rate of 10 nL/min. These mice were retumed to their home cages after
microinjection. One day after microjnjection, mice were used for the behavioral study.
Place conditioning
  Place conditioning study was conducted as previously described in Chapter 2. To
examine the effect of microinjection with ACM and MCM in the rewarding effects
induced by METH and MRP, microinjection of either DMEM, ACM, DMEM + AG490
(O.1 nmol), ACM+AG490 (O.1 nmol), METH 10 ptM-ACM or MCM was performed 1
day before the pre-conditioning test.
  The pre-conditioning test was performed as follows: the partition separating the two
compartments was raised to 7 cm above the floor, a neutral platform was inserted along
the seam separating the compartments, and mice that had not been treated with either
drugs or saline were then placed on the platform. The time spent in each compartment
during a 9oo-sec session was recorded automatically using an infrared beam sensor
(KN-80). Conditioning sessions (three for METH or MRP: three for saline) were
started next day after pre-conditioning test and conducted once daily for 6 days.
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Immediately after injection of either METH (O.0625, O.125, O.25, O.5 or lmg/kg, s.c.) or
MRP (1, 1.7, 3, 5 or 5.6 mg/kg, s.c.); these animals were placed in the compartment
opposite that in which they had spent the most time in the pre-conditioning test, for 1 hr.
On the day after the final conditioning session, these animals were placed in the test
apparatus without any confinements, and then the relative amount of time spent in these
compartments was measured (post-conditioning). The preference for drug-paired
place was shown as mean difference between time spent during the post-conditioning
and pre-conditioning tests. Each preference score represents the mean Å} SEM of 7-8
mice.
Differentiation experiments
  MEB5 (IF050472, the Japanese Cancer Research Resources Bank) was used as
multipotent neural stem cells (NSCs). MEB5 is a multipotent stem cell line that can
differentiate into neurons, astrocytes and oligodendrocytes. The cells were plated in
uncoated plastic tissue flasks and maintained at 37 eC and 5 9o C02. The cells were
cultured in serum-free medium: DMEM with 4,5oo mg/L glucose, 5 ug/mL insulin, 10
ng/mL erythropoietic growth factor (EGF, 50 pglmL transferrin, 10 nglmL biotin and 30
nM Na2Se03. EGF (10 ng/mL) was used to keep the cultures proliferating. For
differentiation experiments, approximately 10 neurospheres of the same size were
plated onto 10 pg/mL laminin-coated glass slides and 400 ptL of serum-free medium
with 10 ng/mL EGF was then added to each well. To determine whether ACM or
METH could induce astrocytic differentiation from neural stem cells, neural stem cells
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were exposed to medium containing, ACM, ACM + AG490 (1 ptM) or METH (10 ptM)
for 5 days. The medium was replaced with fresh medium every 2 days. Ten days after
drug treatment, these cells were washed in PBS, and fixed in 4 9o paraformaldehyde in
phosphate buffer at pH 7.4 and room temperature for 30 min. Thereafter, these cells
were stained for GFAP.
  Astrocytes with processes longer than their perinuclear diameters were defined as
stellate cells according to the criteria used by Kimelberg et alpa) and Shao et al9S. The
experiments were repeatedly performed by, at least, 3 independent astrocyte culture
preparations. The percentage of stellate cells in each experimental condition was
expressed as a percent increase (mean Å} SEM) with respect to that in control cells.
Cytokine array
  To assay the components of astrocyte-released solved factors, I used RayBioTM
Mouse Cytokine Array (RayBiotech Inc. Norcross, GA, USA). According to the
manufacture's protocol, either DMEM, ACM or METH 10 ptM-ACM was incubated
with RayBio'M Mouse Cytokine Array membranes, which were conjugated with anti-
cytokine antibodies. After this incubation, membranes were exposed to x-ray film.
Film autoradiograms were analyzed and quantified by computer-assisted densitometry
using an NIH Image.
Statistical analysis
  The data of GFAP-like immunoreactivity, astrocyte differentiation and cytokine assay
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are presented as the mean (percent of control) Å} SEM. The statistical significance of
differences between the groups was assessed by one-way ANOVA with Student's t-test.
  Conditioning scores were obtained by subtracting the cumulative time (sec) spent in
the saline-paired side from that in the drug-paired side, were expressed as means Å} SEM.
A statistical analysis for place conditioning study was performed using one-way
ANOVA followed by BonferronilDunnett's test.
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Resuks
The effect of the glial modulator propentofy11ine (PPF)
  In the present study, I used mouse conical neuronlglia co-cultures to confirm the
effect of PPF, which is known to modulate glial activity under pathological conditions96'
9", in the activation of astrocytes induced by METH and MRP. The activation of
astrocytes induced by either METH or MRP was dramatically diminished by treatment
with PPF (Figure 3-IA, B).
  I next investigated the effect of PPF on the respective rewarding effects of METH
and MRP in mice using the conditioned place preference paradigm. Mice conditioned
with METH (1 mglkg, s.c.) or MRP (5 mg/kg, s.c.) exhibited a significant preference for
the drug-associated place (23.8 Å} 17.9 sec for saline-saline, 163.8 Å} 22.0 sec for saline-1
mg/kg METH; p Åq O.oo1 vs. saline-saline, 118.9 Å} 30.5 sec for saline-5 mglkg MRP; p
Åq O.Ol vs. saline-saline, Figure 3-IC). PPF (3 mg/kg, i.p.) alone did not induce either
significant place preference or place aversion in mice (-3.0 Å} 22.1 sec). Under these
conditions, the significant place preference produced by either METH or MPR was
suppressed by treatment with PPF (60.4 Å} 15.4 sec for 3 mg/kg PPF-1 mg/kg METH; p
Åq O.Ol vs. saline-1 mglkg METH, 40.1 Å} 17.7 sec for 3 mg/kg PPF-5 mglkg MRP; p Åq
O.05 vs. saline-5 mglkg MRP, Figure 3-IC). These results indicate that gliaJ cells may
be involved in the development of the rewarding effects induced by METH and MRP in
mice.
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Administration of astrocyte-conditioned medium (ACM) enhances the rewarding
effects of METH hnd MRP
  It is well known that the N.Acc. plays an important role in mediating the rewarding
effects induced bY many drugs of abuse`3' "). On the other hand, astrocyte could
regulate the neuronal transmission by releasing neurotransmitters4), neurotrophic factors
98' op), cytokinesas'as), chemokines23-as), and extracellular matrix98). To examine the role
of astrocyte-related soluble factors in the development of the rewarding effects induced
by drugs of abuse, ACM was injected into the N.Acc. (Figure 3-2A). In animals in
which DMEM was injected into N.Acc., METH (O.0625, O.125, O.25 or O.5 mg/kg, s.c.)
and MRP (1, 1.7, 3 or 5.6 mg/kg, s.c.) each produced a dose-dependent preference for
the drug-associated place (4 Å} 16.9 sec for DMEM-saline, 18.0 Å} 19.5 sec for DMEM-
O.0625 mglkg METH, 34. 1 Å} 14.6 sec for DMEM-O.125 mglkg METH, 62.3 Å} 25.5 sec
for O.25 mg/kg METH; p Åq O.05 vs. DMEM-saline, 94.4 Å} 25.7 sec for DMEM-O.5
mg/kg METH; p Åq O.05 vs. DMEM-saline, 4.8 Å} 20.3 sec for DMEM-1 mglkg MRP,
26.6 Å} 9.9 sec for 1.7 mg/kg MPR, 67.9 Å} 18.1 sec for 3 mg/kg MRP; p Åq O.05 vs.
DMEM-saline, 98.9 Å} 9.9 sec for 5.6 mg/kg; p Åq O.oo1 vs. DMEM-saline, Figure 3-2B,
C). Under these conditions, intra-N.Acc. administration ofACM clearly enhanced the
rewarding effects of METH (36.6 Å} 7.6 sec forACM-O.0625 mg/kg METH, 54.7 Å} 38.0
sec for ACM-O.125 mg/kg METH, 138.5 Å} 25.2 sec forACM-O.25 mg/kg METH: p Åq
O.05 vs. DMEM-O.25 mglkg METH, 172.0 Å} 18.2 sec for ACM-O.5 mg/kg METH; p Åq
O.Ol vs. DMEM-O.5 mg/kg METH, Figure 3-2B) and MRP (7.0 Å} 8.7 sec for ACM-1
mglkg MRP, 65.9 Å} 21.1 sec for ACM-1.7 mg/kg MRP, 135.7 Å} 22.7 sec for ACM-3
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mg/kg MRP; p Åq O.Ol vs. DMEM-3 mg/kg MRP, 145.7 Å} 23.1 sec for 5.6 mg/kg MRP,
Figure 3-2C) in mice.
The implication of Jak/STAT pathway in the enhancement by ACM of METH- and
MRP-induced rewardmg effects
  The JaklSTAT is a pathway that takes signals from the cell membrane to the nucleus
in response to extracellular growth factors and cytokines'oo). In addition, the JaklSTAT
pathway has been postulated to regulate astrogliosis and astrogliogenesis'O'-'os). The
place preference produced by MRP (3 mg/kg, s.c.), but not METH (O.5 mglkg, s.c.), was
significantly suppressed by intra-N.Acc. treatment with AG490 (O.1 nmol), which
inhibits the JaklSTAT pathway (11.2 Å} 16.6 sec forAG490 + DMEM-3mg/kg MRP; p Åq
O.05 vs. DMEM-3 mglkg MRP, Figure 3-3B, 64.4 Å} 24.8 sec for AG490 + DMEM-O.5
mglkg METH; no significance vs. DMEM-O.5 mg/kg METH, Figure 3-3A). Notably,
the enhancement of the rewarding effect of METH by ACM was significantly blocked
by intra-N.Acc. treatment with AG490 (O.1 nmol, 70.2 Å} 17.7 sec for AG490 + ACM-
O.5 mg/kg METH; p Åq O.05 vs. ACM-O.5 mglkg METH, Figure 3-3A). These results
raise the possibility that astrocyte-related soluble factors could regulate the development
of the rewarding effects induced by drugs of abuse via Jak/STAT pathway. Moreover,
Jak/STAT-dependent astrogliosis and/or astrogliogenesis may play the important role
during the development of the rewarding effects induced by drugs of abuse.
The effects of ACM on the differentiation of multipotent neural stem cells (NSC)
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via Jak/STAT pathway
  To ascertain whether ACM could induce JaklSTAT-dependent astrogliogenesis, I
performed the differentiation experiments using multipotent neural stem cells obtained
from the mouse forebrain. ACM clearly induced the differentiation of multipotent
NSCs into GFAP-positive astrocytes (Figure 3-4A, C). This effect was reversed by co-
treatment with AG490 (1 pM, Figure 3-4A, C). Conversely, treatment of NSCs with
METH (10 ptM) failed to induce the differentiation to GFAP-positive astrocytes (Figure
3-4B, D), indicating that ACM, but not METH itself, may induce astrogliogenesis via
the JaklSTAT pathway in the CNS.
The effect of METH-treated astrocyte-conditioned medium
  To examine whether ACM could promote astrogliosis, I next investigated the effect of
ACM in the level of GFAP-like immunoreactiviry in purified cortical astrocytes.
Treatment with DMEM or ACM for 1 day did not produce a significant increase in the
level of GFAP-like immunoreactivity in purified cortical astrocytes (Figure 3-5A, B).
Treatment with ACM collected from METH (10, 100 ptM, 3 days)--treated astrocytes
(METH 10 ptM-ACM, METH 1oo ptM-ACM) for 1 day induced a robust activation of
astrocyte, as detected by an increase in the level of GFAP-like immunoreactivity, in
purified conical astrocytes (p Åq O.Ol, p Åq O.oo1 vs. DMEM-treated cells, Figure 3-5A,
B). On the other hand, treatment with ACM collected from MRP (10-1oo ptM, 3
days)-treated astrocytes did not produce any morphological changes in purified cortical
astrocytes (Figure 3-5A, B). These results suggest that METH-, but not MRP-, treated
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astrocytes could release some soluble factors which could enhance the activation of
astrocytes.
  As described in Chapter 1, in vitro treatment with 1oo ptM of METH caused neuronal
cell death. On the other hand, in vitro treatment with 10 ptM of METH could cause the
activation of astrocytes without neuronal cell death. Therefore, 1oo ptM of METH
might have some neurotoxic effects. In the present study, intra-N.Acc. administration
of METH 10 ptM-ACM dramatically enhanced the rewarding effects of METH (252.6 Å}
47.0 sec for METH 10 ptM-ACM-O.5 mg/kg METH; p Åq O.05 ys. ACM-O.5 mglkg
METH, Figure 3-5C), indicating that astrocyte-related soluble factors released form
METH-treated astrocytes potentiate the expression of the rewarding efifect induced by
METH.
ACM contains some chemokines
  As mentioned aboye, the Jak/STAT pathway could modulate the deyelopment of the
rewarding effects induced by METH and MRP. The JaklSTAT pathway is coupled to
many key cytokine/chemokine receptors and is thus a primary conduit for
cytokinelchemokine signal transduction and cellular communication'ca). Therefore, I
hypothesized that astrocyte-related cytokines andlor chemokines may contribute to the
development of the rewarding effects induced by METH and MRP. Based on this
hypothesis,Inext performed the cytokine assay. Ifound that some chemokines, such
as monocyte chemoattractant protein-5 (MCP-5) and soluble tumor necrosis factor
receptor 1 (sTNFRI), were identified in both ACM and METH 10 pM-ACM (Figure 3-
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6A, B).
The effect of intra-N.Acc. administration of microglia-conditioned medium (MCM)
on the rewarding effect induced by METH and MRP
  Microglial cells are the major immunocompetent cells in the brain and include
signaling cascades including cytokines and chemokinesi05). Therefore, I next
investigated the effect of microgia-related soluble factors on the development of the
rewarding effects induced by METH and MRP.
  Treatment with METH (10-100 pM) for 3 days in purified cortical microglia caused a
swelling morphology and an increase in the level of immunoreactivity of OX-42, which
is a specific marker of microglia (Figure 3-7A). On the other hand, treatment with
MRP (1-1oo ptM, 3 days) failed to induce any morphological changes in purified
cortical microglia (Figure 3-7A).
  In contrast to ACM, however, intra-N.Acc. administration of MCM failed to enhance
the rewarding effects induced by METH (147.0 Å} 19.3 sec for MCM-O.5 mg/kg METH;
no significance vs. DMEM-O.5 mglkg METH, Figure 3-7B) and MRP (82.1 Å} 16.3 sec
for MCM-3 mglkg MRP; no significance vs. DMEM- 3 mglkg MRP, Figure 3-7C) in
               '
mice.
The effect of intra-CG administration ofACM on the rewarding effect induced by
METH and MRP
  The CG is responsible for psychostimulant-induced rewarding effects and leaming'D.
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To compare the effect of intra--N.Acc. administration of ACM, I next investigated the
effect of intra--CG administration ofACM on the rewarding effect of METH and MRP.
In animals in which DMEM was injected into the CG, METH (O.0625, O.125, O.25 or
O.5 mg/kg, s.c.) and MRP (1, 1.7, 3 or 5.6 mg/kg, s.c.) produced a dose-dependent
preference for the drug-associated place (- 1.8 Å} 13.5 sec for DMEM-saline, 20.9 Å} 28.8
sec for DMEM-O.0625 mglkg METH, 36. 1 Å} 10.6 sec for DMEM-O.125 mglkg METH,
71.6 Å} 14.5 sec for DMEM-O.25 mglkg METH; p Åq O.05 vs. DMEM-saline, 94.4 Å} 25.8
sec for DMEM-O.5 mg/kg METH; p Åq O.OOI ys. DMEM-saline, 28.9 Å} 17.6 sec for
DMEM-1 mg/kg MRP, 13.4 Å} 21.3 sec for DMEM-1.7 mg/kg MRP, 60.4 Å} 24.7 sec for
DMEM--3 mglkg MRP; p Åq O.05 vs. DMEM-saline, 117.1 Å} 20.0 sec for DMEM-5.6
mglkg MRP: p Åq O.ool vs. DMEM-saline, Figure 3-8B, C). Under these conditions,
intra-CG administration of ACM clearly enhanced the rewarding effect of METH (37.2
Å} 22.4 sec for ACM-O.0625 mg/kg METH, 66.0 Å} 12.1 sec for ACM-O.125 mglkg
METH, 145.9 Å} 26.7 sec forACM-O.25 mg/kg METH; p Åq O.05 vs. DMEM-O.25 mglkg
METH, 172.0 Å} 29.1 sec for ACM-O.5 mglkg METH; p Åq O.Ol vs. DMEM-O.5 mg/kg
METH, Figure 3-8B) and MRP (11.4 Å} 17.1 sec for ACM-1 mgfkg MRP, 70.3 Å} 15.1
sec for ACM-1.7 mg/kg MRP; p Åq O.05 vs. DMEM-1.7 mglkg MRP, 141. 9 Å} 12.5 sec
for ACM-3 mglkg MRP; p Åq O.Ol vs. DMEM-3 mg/kg MRP, 169.1 Å} 8.6 sec forACM-
5.6 mg/kg MRP; p Åq O.05 vs. DMEM-3 mglkg MRP, Figure 3-8C) in mice.
The effect of intra-corpus striatum (CPu) administration of
rewarding effect induced by METH and MRP
                        78
ACM on the
  The CPu is regulated by dopaminergic inputs from the substantia nigra. Intra-CPu
administration of ACM failed to enhance the rewarding effects induced by METH
(101.1 Å} 16.4 sec for DMEM-O.5 mglkg METH, 99.9 Å} 13.7 sec for ACM-O.5 mglkg
METH; no significance vs. DMEM-O.5 mglkg METH, Figure 3-9B) and MRP (81.9 Å}
15.6 sec for DMEM-3 mglkg MRP, 87.1 Å} 21.1 sec for ACM-3 mglkg MRP; no
significance vs. DMEM-3 mg/kg MRP, Figure 3-9C) in mice.
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In purified cortical astrocytes
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Figure 3-5 The et't'ect of intra-N.Acc, administration of METH (10 stM. 3 days)-trcated conditioned medium
(METH 10 ptM-ACM) on the place conditionitig produccd by METH in tnice. (A) Purifiedcortic'al astrocytes
were treated with DMEM, ACM. METH (10.100 yM. 3 days)-treatcd astr{rcyte-conditioned medium (METH 1O
ytM-ACM or METH 100 "M-ACM). or MRP(1O. 1OO ItM. r, d:ty: )-treated astrocyte-conditioned medium (MRP
10 ptM-ACM or MRP 100 sLM-ACM). The ceils were stained with a polyclonal antibody to GFAP, (B) The
intensity of GFAP-likc immunoreactivity ineach imagewas measuredusing NIH-image, The leve] ofGFAP-like
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potentiared the rewarding effect of METH (O.5 m.a.!kg, t ,c,) in mice. Each column represents the mean Å} SEM of
8 micc. "p Åq O.05. :]'::i: 'E`p Åq O.OOI vs, DMEM-saline group: #p ÅqO.05. 'M"p Åq O.OOi v: . DMEMK).5 m.u.fkg. METH
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Figure 3-6 Cytokine array of DMEM, ACM and METH 10 pM-ACM. DMEM (control), ACM or
METHIO-AC.M was incubated with cytokine array membranes using anti-cytokine antibodics. The
changes in the immunoreactivity of monocyte chemotactic protein-5 (MCP-5. A) and tumor necrosis
factor soluble receptor-1 (sTNFR, B) are expressed as a percent increase (mean Å} SEM) with respect to
that in contrx ,1 (DMEM) cells. "p Åq O.05 vs. control.
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(A) In purified cortical microglia
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the placc conditioning produced by bvlE'['H and MRP in niice. (A) 1'uril'ied cortical tnicro.glia "'ere
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Figure 3-8 The effect of intra-cingulate cortex (CG) administration of astrocyte-conditioned medium
(ACM) on the place conditioning produced by METH and MRP in mice. (A) Dots represent
microinjection regions in mice. The schematic brain sections are from the atlas93). (B) Mice were
pretreated with DMEM or AC.M into the CG 1 day before pre-conditioning test. In the conditioning
session (three days for METH. three days for saline), mice were treated svith saline or METH (O.0625,
O.125. 0.25 or O.5 mglkg, s.c.). Each point represents the mean Å} SEM of 7-8 mice. (C) Mice svere
pretreated with DMEM or ACM into the CG I day before pre-conditioning test. In the conditioning
session (three days for MRP, three days for saline), mice svere treated wlth saline or maP(1, 1.7, 3 or 5.6
mg!kg. s.c.), Each point represents the mean Å} SEM of 78 mice. *pÅq O.05, "**p ÅqO.OOI vs. DMEM-
sal ine gK)up; #p Åq O, 05. Wp Åq O.O1 vs. DMEM pretreated group.
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Discussion
  In the present study, I investigated the direct action of astrocytes on the development
of the rewarding effects induced by drugs of abuse. I found here that astrocyte-, but
not microglia-, related soluble factors may directly modulate the development of the
rewarding effects induced by METH and MRP.
  PPF is a xanthine derivative with pharmacological effects different from those of the
classical methylxanthines, caffeine, and theophylline. PPF is known to modulate glial
activity under pathological condition96' 9D. The mechanism of glial modulation by PPF
under pathological condition could be due to its inhibitory action of phosphodiesterase
enzymes and subsequent augmentation of cyclic-AMP signalingioo). It has been
reported that the activity of cyclic-AMP could regulate the morphology of astrocytesiO').
In the present study, I found that the METH- or MRP-induced activation of astrocytes
was dramatically diminished by treatment with PPF. Thus, PPF may inhibit the
activity of phosphodiesterase in astrocytes, resulting in the inhibition of the activation of
astrocytes. I also demonstrated that the place preference produced by repeated in vivo
treatment of either METH or MRP was significantly suppressed by i.p. treatment with
the g}ial modulator PPE These findings provide the evidence that the modulatjon of
glial activity may contribute to the development of the rewarding effects induced by
METH and MRP.
  I next examined whether astrocyte-related soluble factors could regulate the
development of psychological modulation on METH and MRP. In the present study,
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intra-N.Acc. administration of ACM dramatically enhanced the rewarding effects of
METH and MRP. These data suggest that astrocyte-related soluble factors induced by
drugs of abuse may directly regulate the development of their rewarding effects.
  Chronic administration of cocaine induces the up-regulation of the JaklSTAT pathway
in the VTA'os). It has been reported that treatment with METH at neurotoxic doses
induces the robust phosphorylation of STAT3 in the mouse brain'oo). These findings
raise the possibility that exposure to the drugs of abuse could produce the synaptic
plasticity and/or neuronal toxicity via the Jak/STAT pathway. In the present study, the
enhancement of METH-induced rewarding effects by ACM was blocked by intra-N.Acc.
administration of the Jak/STAT inhibitor AG490, suggesting that astrocyte-related
soluble factors enhance the development of METH-induced rewarding effects via the
Jak/STAT pathway.
  p-Opioid receptors, which have been reported to play a role in several of MRP's
pharmacological effects, are member of the G protein-coupled-receptor superfamilyi'O).
Agonist stimulation of many G-protein-coupled receptors has been shown to result in
tyrosine phosphorylation and activation of Jak and STAT family members, leading to
changes in gene transcriptionica). It has been reported that STAT3 signaling regulates
the neuronal growth and differentiation by pt-opioid receptor stimulation in
neuroblastoma SH-SY5Y cells"'). MRP exposed to COS-7 cells, which are transfected
with pt-opioid receptors and STAT5A, induces receptor--dependent tyrosine
phosphorylation of STAT5A"2). In the present study, I demonstrated that both the
expression of and ACM-induced enhancement of MRP-induced rewarding effects were
                                    oo
blocked by intra-N.Acc. administration of AG490. Thus, it seems likely that chronic
treatment with MRP may activate the Jak/STAT pathway via pt-opioid receptors,
resulting in the development and expression of rewarding effects in mice.
  The Jak/STAT pathway modulates astrogliosis and/or astrogliogenesis'Oi"os). It
should be mentioned that ACM, but not METH itself, induced the differentiation of
NSCs into GFAP-positive astrocytes via Jak/STAT pathway. On the other hand, the
treatment with METH-ACM, but not ACM or MRP-ACM, induced the activation of
astrocytes in purified conical astrocytes. Furthermore, intra-N.Acc. administration of
METH-ACM significantly and dramatically enhanced the rewarding effect of METH.
These findings suggest that astrocyte-related soluble factors could cause
astrogliogenesis via the JaklSTAT pathway, promoting the development and expression
of rewarding effect induced by METH. Moreover, METH-induced astrocytic secretion
might enhance the intensity of astrocytic activation in the CNS. Although the exact
binding site for METH in astrocytes or the mechanism underlying METH-induced
astrocytic secretion is unclear at this time, METH, which could be taken up by
astrocytes across the astrocytic plasma membranes, causes astrocytic secretion, and
potentiates the development of the rewarding effect induced by METH.
  In the present study, I also observed the difference between METH-ACM and MRP-
ACM; while METH-ACM markedly activated astrocytes with morphological changes
in astrocytes, MRP-ACM had no such effect. The data suggest that METH, but not
MRP, may directly affect astrocytes and lead to the release of astrocyte-related soluble
factors, resulting in the robust enhancement of the development of the rewarding effect
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induced by METH.
  The Jak/STAT pathway transduces signals from cytokines and chemokines. In the
present study, some chemokiens, such as MCP-5 and sTNFRI, were identified in ACM
and METH-ACM. MCP-5 is a mouse homologue to MPC-1i'3). In addition,
treatment with MRP induces the secretion of MCP-1 from astrocytesii3). On the other
hand, the biological functions of the sTNFRI are not completely understood. TNF-ct
and other cytokines can bind to this receptorii`). Some kinds of drugs of abuse, such as
MRP"S and METHii6), could induce the generation of TNF-ct, which may in turn
stimulate the release of sTNFRI as astrocyte-related soluble factors. Collectively,
these astrocyte-related chemokines may, at least in part, contribute to the positive
regulation of neuron-glia communication during the development of the rewarding
effects induced by drugs of abuse.
  Cytokines, chemokines and their receptors play a major role in the immune responses
of the CNS. They are expressed at constitutively low levels in microglia, and induced
by inflammatory mediatorsi05'iiD. Moreover, microglial cells are known to response to
drugs of abuse, such as MRP and METH59' '3' 'i8). In the present study, treatment with
METH caused a morphological change in purified cortical microglia, whereas MRP had
no such effect. In contrast to ACM, intra-N.Acc. administration of MCM failed to
enhance the rewarding effects induced by METH and MRP. Thus, it seems likely that
METH-induced morphological changes in cortical microglia are not essential for the
development of METH-induced rewarding effect. Collectively, these findings indicate
that astrocyte-, but not microglia-, related soluble factors could potentially regulate the
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development of the rewarding effects induced by drugs of abuse.
  It is of interest to note that intra-CG administration of ACM also significantly
enhanced the rewarding effects of METH and MRP. The CG projects to the
mediodorsal caudate, lateral part of the mediodorsal nucleus of the thalamus, and
amygdala"9). In addition, CG receives major dopaminergic input from the VTAi2e).
The CG is, therefore, linked to emotional states and responsible for rewarding and
leaming'D. Taken together, these results indicate that astrocyte-related soluble factors
directly modify the neuron/glia communication in the CG during the development of the
rewarding effects induced by METH and MRP.
  Unlike intra-N.Acc. and intra-CG administration of ACM, intra-CPu administration
ofACM failed to enhance the rewarding effects induced by METH and MRP. These
data suggest that astrocyte-related soluble factors could regulate the development of the
rewarding effect induced by drugs of abuse in specific brain regions, such as the N.Acc.
and CG.
  In conclusion, I demonstrated here that the activation of astrocytes in the N.Acc.
and/or CG provides a powerful signal for dopamine-associated behaviors, habits and
addiction by drugs of abuse at the synaptic levels. My findings suggest that astrocyte-,
but not microglia-, related soluble factors could directly amplify the development of
rewarding effect induced by METH and MRP in the N.Acc. and CG. The present
findings provide a new insight into the basis of synaptic plasticity during the
development of the rewarding effects induced by drugs of abuse.
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General Conclusion
The above findings lead to the following conclusions:
In Chapter 1:
  In this study, I found that in vitro treatment of cortical neuronlglia co-cultures with
either METH or MRP caused the activation of astrocytes via PKC. In purified cortical
astrocytes, astrocytes were markedly activated by METH, whereas MRP had no such
effect. METH, but not MRP, caused a Iong-lasting astrocytic activation in cortical
neuronlglia co-cultures. Furthermore, MRP-induced behavioral sensitization to
hyperlocomotion was reversed by 2 months of withdrawal following intermittent MRP
administration, whereas behavioral sensitization to METH-induced hyperlocomotion
was maintained even after 2 months of withdrawal. In vivo treatment with METH,
which was associated with behavioral sensitization, caused PKC-dependent astrocytic
activation in the mouse CG and N.Acc.. These findings provide direct evidence that
METH induces long-lasting astrocytic activation and behavioral sensitization through
the stimulation of PKC in the rodent brain. In contrast, MRP produced a reversible
activation of astrocytes via neuronal PKC and a reversibility of behavioral sensitization.
This information can break through the definition of drugs of abuse and the misleading
concept that MRP produces long-lasting neurotoxicity.
In Chapter2:
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  I demonstrated that in vitro treatment with METH caused the phosphorylation of both
neuronal and astrocytic PKC and the activation of astrocytes in conical neuron/glia co-
cultures. Treatment of conical neuron/glia co-cultures with either the PKC activator
PDBu or glutamate also caused the PKC-dependent activation of astrocytes. The PKC
inhibitor CHE suppressed the Ca2' responses to glutamate in both conical neurons and
astrocytes. Notably, treatment with METH also enhanced the Ca2' responses to
glutamate in cortical neurons. The activation of astrocytes induced by METH was also
reversed by co-treatment with glutamate receptor antagonists in cortical neuronlglia co-
cultures. In the conditioned place preference paradigm, i.c.v. administration of
glutamate receptor antagonists attenuated the METH-induced rewarding effect. These
findings provide evidence that the changes in PKC-dependent neuronal and astrocytic
glutamatergic transmission induced by METH may, at least in part, contribute to the
development of the rewarding effect induced by METH.
In Chapter 3:
  I found that the glial modulator PPF dramatically diminished the activation of
astrocytes induced by METH and MRP. In vivo treatment with PPF also suppressed
the rewarding effects induced by both METH and MRP. On the other hand, intra-
N.Acc. administration of ACM aggravated the development of rewarding effects
induced by METH and MRP via the Jak/STAT pathway. Furthermore, ACM, but not
METH itself, clearly induced the differentiation of NSCs into astrocytes. Intra-CG,
but not -CPu, administration of ACM also enhanced the rewarding effects induced by
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METH and MRP. These findings suggest that astrocyte-related soluble factors could
amplify the development of the rewarding effects of METH and MRP in the N.Acc. and
CG. The present study provides direct evidence that astrocytes may, at least in part,
contribute to the synaptic plasticity induced by drugs of abuse during the development
of the rewarding effects induced by METH and MRP. The present findings provide
new insight into astrocytic modulation of synaptic plasticity during the development of
psychological dependence on drugs of abuse.
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